var title_f5_55_6000="Cicatrix concealed penis";
var content_f5_55_6000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cicatrix concealed penis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 154px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Concealed penis after circumcision due to cicatrix formation.",
"    <br>",
"     (A) The cicatricial scar (distal arrows) traps and hides the penis. There is no exposed shaft skin. Note penile position (black arrow).",
"     <br>",
"      (B) The tight circumferential scar (arrows) is incised and the penis is exposed. Almost all shaft skin was previously removed.",
"      <br>",
"       (C) Surgical correction used skin multiple Z-plasties (arrows) for scrotal skin flaps to compensate for the lack of penile skin.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced from: Casale A, Beck S, Cain M, et al. Concealed penis in childhood: A spectrum of etiology and treatment. J Urol 1999; 162:1165. Copyright &copy; 1999. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6000=[""].join("\n");
var outline_f5_55_6000=null;
var title_f5_55_6001="Prepubertal vaginal examination using a Killian nasal speculum";
var content_f5_55_6001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Vaginal examination of patient under anesthesia, using a Killian nasal speculum with fiberoptic light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6001=[""].join("\n");
var outline_f5_55_6001=null;
var title_f5_55_6002="von Willebrand disease";
var content_f5_55_6002=[" <h1 id=\"patTopicTitle\">",
"  Patient information: von Willebrand disease (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/55/6002/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6002/contributors\" id=\"au4497\">",
"       Margaret E Rick, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/55/6002/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6002/contributors\" id=\"se1211\">",
"       Lawrence LK Leung, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/55/6002/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6002/contributors\" id=\"de8736\">",
"       Jennifer S Tirnauer, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6002/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?5/55/6002?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      VON WILLEBRAND DISEASE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     When people think of medical disorders that cause excessive or uncontrolled bleeding, they usually think of hemophilia. That's understandable, given that hemophilia is often mentioned in popular culture. But, the truth is that von Willebrand disease is a much more common bleeding disorder than hemophilia, affecting roughly 1 percent of the population.",
"    </p>",
"    <p>",
"     Although more common than hemophilia, von Willebrand disease is usually less serious. Many people with von Willebrand disease have such mild symptoms that they do not learn they have the disorder until well into adulthood. Often the first clues come during surgery or after a serious injury, when bleeding will not stop.",
"    </p>",
"    <p>",
"     If you are cut or injured, tiny cell fragments that circulate in the blood, called platelets, collect at the site to form a plug to stop the bleeding. Von Willebrand factor is essential to this process, because it is the \"glue\" that binds platelets to one another and to the lining of the blood vessel. Von Willebrand factor also protects another important clotting factor (factor 8, written as factor VIII), from being broken down.",
"    </p>",
"    <p>",
"     Von Willebrand disease is most often caused by genetic mutations that either impair your ability to make von Willebrand factor or lead to the production of defective forms of the protein. In rare instances, von Willebrand disease can be \"acquired,\" meaning it is not inherited and instead arises because of the presence of another illness or the use of certain drugs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF VON WILLEBRAND DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     The inherited forms of von Willebrand disease are classified as (or present as) three different types:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Type 1",
"     </span>",
"     &nbsp;&mdash;&nbsp;Type 1 is the most common form, affecting 75 percent of those who have the disorder. People with this type make insufficient amounts of von Willebrand factor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Type 2",
"     </span>",
"     &nbsp;&mdash;&nbsp;Type 2 is the second most common form, and causes people to make defective forms of von Willebrand factor. This type can be broken down into 4 different subtypes. If you have type 2, your healthcare provider can explain the subtype you have in more detail.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Type 3",
"     </span>",
"     &nbsp;&mdash;&nbsp;Type 3 is the rarest form of von Willebrand disease, and causes a total deficiency of the protein. This type is usually detected early in life because it leads to the most severe and obvious bleeding symptoms.",
"    </p>",
"    <p>",
"     Finding out which type you have is an important step in getting the right treatment. Knowing what type you have is particularly important in helping healthcare providers control bleeding in emergency situations. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"      \"Classification and pathophysiology of von Willebrand disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Carry this information and a list of any other medical problems and medications on a medical identification card or bracelet (see",
"     <a class=\"local\" href=\"#H9\">",
"      'Lifestyle changes and self care with von Willebrand disease'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      VON WILLEBRAND DISEASE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of von Willebrand disease are often very mild. Sometimes, a person will learn that something is wrong only after they are faced with a \"bleeding challenge,\" such as a major injury, surgery, or childbirth. However, once you learn that you have the disorder, you may remember instances in which you bled more than normal. For example, you may recall:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Getting frequent or long-lasting nosebleeds",
"      </li>",
"      <li>",
"       Gum bleeding with no apparent cause",
"      </li>",
"      <li>",
"       Bruising easily with lumps forming under the bruise",
"      </li>",
"      <li>",
"       Having especially heavy or long-lasting periods (if you are a woman), lasting longer than seven to 10 days and with large blood clots",
"      </li>",
"      <li>",
"       Bleeding more than expected during dental work or minor medical procedures and for a prolonged time after surgical procedures",
"      </li>",
"      <li>",
"       Bleeding when you took aspirin or related drugs called nonsteroidal anti-inflammatory drugs (NSAIDs), all of which inhibit clotting",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      VON WILLEBRAND DISEASE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If your healthcare provider suspects you have von Willebrand disease, he or she will want to learn as much as possible about your \"bleeding history.\" He or she will ask if you often get nosebleeds, bruise easily, or have had any of the other symptoms mentioned above. Since von Willebrand disease runs in families, your healthcare provider will also want to know if any of your relatives have the disorder. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"      \"Clinical presentation and diagnosis of von Willebrand disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Lab tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;You may have to provide one or more blood samples so that your healthcare provider can measure how much von Willebrand factor you make and test whether your von Willebrand factor protein functions normally.",
"    </p>",
"    <p>",
"     The initial tests used to diagnose von Willebrand disease include the:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       von Willebrand factor antigen test &mdash; This test measures the amount of von Willebrand factor in your blood.",
"      </li>",
"      <li>",
"       von Willebrand factor activity test &mdash; This test measures how well your von Willebrand factor works. A commonly used von Willebrand factor activity test is called the Ristocetin cofactor test.",
"      </li>",
"      <li>",
"       Factor VIII activity test &mdash; Factor VIII (factor 8) is another protein involved in clotting; it circulates in the blood attached to and protected by von Willebrand factor. Because of this, your healthcare provider will also determine the levels of factor VIII in your blood.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If any of these tests are abnormal, your healthcare provider may repeat the tests",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     run additional, more sophisticated tests. The results of all of these tests will help your healthcare provider determine what type of von Willebrand disease you have and how severe it is.",
"    </p>",
"    <p>",
"     When any of these tests are performed, your clinician will notify you of the results and what they mean in terms of diagnosis and classifying your type of von Willebrand disease. He or she can also discuss which form(s) of treatment might be required.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      LIFESTYLE CHANGES AND SELF CARE WITH VON WILLEBRAND DISEASE",
"     </span>",
"    </p>",
"    <p>",
"     If you are diagnosed with von Willebrand disease, your healthcare provider may recommend that you avoid aspirin, NSAIDs",
"     <span class=\"nowrap\">",
"      (ibuprofen/Advil&reg;,",
"     </span>",
"     <span class=\"nowrap\">",
"      naproxen/Aleve&reg;,",
"     </span>",
"     and others), and any other drugs that inhibit clotting or \"thin the blood.\" If you need a medication for pain or fever relief, acetaminophen (Tylenol&reg;) is a safe alternative to aspirin and NSAIDs.",
"    </p>",
"    <p>",
"     Depending on the severity of your von Willebrand disease, you may also have to take special precautions to avoid injuries, such as avoiding contact sports. However, precautions are not necessary for most people with type 1 and some with type 2 von Willebrand disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Planning for surgery and childbirth",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you learn that you need surgery, including dental surgery, you should discuss your von Willebrand disease with your surgeon or dentist ahead of time.",
"    </p>",
"    <p>",
"     If you become pregnant or want to do so, you should also discuss your von Willebrand disease with your obstetrician or primary care doctor. These discussions will help your healthcare providers develop a plan to control your bleeding before it becomes a problem.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      VON WILLEBRAND DISEASE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Once your healthcare provider knows what type of von Willebrand disease you have, he or she can recommend an appropriate treatment. You and your healthcare provider may have to try one or two different treatment regimens before you find the one that works best for you. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link\">",
"      \"Treatment of von Willebrand disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Depending on the type and severity of von Willebrand disease you have, you may get treatments that:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Increase your own production of von Willebrand factor &mdash; This is usually done with a drug called desmopressin (DDAVP&reg;; Stimate&reg;), which you can take as a nasal spray or as an injection. Your clinician will give you more detailed instructions as to how to use this medication, how often it can be repeated, what side effects to watch for, and when to call if the medication does not slow your bleeding.",
"       <br/>",
"       <br/>",
"       It is important to understand how to use DDAVP since it can cause unwanted and serious side effects if used at a higher dose or for a longer period than recommended.",
"      </li>",
"      <li>",
"       Replace your missing or deficient von Willebrand factor &mdash; This is usually done by injecting purified forms of the protein directly into your veins. A number of such von Willebrand factor products are available, including Humate P&reg; and Alphanate&reg;. This treatment is done in the hospital or a healthcare provider's office.",
"      </li>",
"      <li>",
"       Prevent clots from dissolving &mdash; This approach involves taking medications, such as aminocaproic acid (Amicar&reg;) or tranexamic acid (Cyklokapron&reg;), in pill form, as a mouthwash, or as an injection that is given into a vein. These medications are especially useful for managing nosebleeds or bleeding from the mouth (for example, following dental work).",
"      </li>",
"      <li>",
"       Stimulate clot formation &mdash; Medications that stimulate the formation of clots are available as a foam strip or gel that is applied to the bleeding area. Your healthcare provider may use this type of treatment for bleeding from the mouth or nose.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Hormones help control menstrual bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with von Willebrand disease are sometimes given hormone treatment in the form of menopausal hormone therapy, the birth control pill, or an intrauterine device (IUD) that releases a hormone called progestin. These hormonal treatments can eliminate or reduce heavy menstrual bleeding. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Acquired von Willebrand disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;People whose von Willebrand disease is associated with another medical condition, such as autoimmune diseases, cancer, or reduced function of the thyroid gland, are sometimes given treatments similar to those described above. For them, treating the underlying condition may also be important in managing the von Willebrand disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Pregnancy and childbirth in women with von Willebrand disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with von Willebrand disease should be monitored closely throughout pregnancy to make sure that bleeding does not become an issue. Most will not need treatment while they are pregnant, because von Willebrand factor production naturally rises during pregnancy. After delivery, however, levels of the protein can drop and lead to serious bleeding. As a result, women may need to take one or more of the treatments described above for one to three weeks following delivery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784881948\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568508\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/32/39425?source=see_link\">",
"      Patient information: von Willebrand disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=see_link\">",
"      Patient information: Taking care of bruises (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11568542\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/index.htm\">",
"      www.nhlbi.nih.gov/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Hemophilia Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hemophilia.org/\">",
"      www.hemophilia.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?5/55/6002/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?5/55/6002?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6002/abstract/1\">",
"      Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6002/abstract/2\">",
"      Pasi KJ, Collins PW, Keeling DM, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6002/abstract/3\">",
"      Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14:171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f5_55_6002=[""].join("\n");
var outline_f5_55_6002=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           VON WILLEBRAND DISEASE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF VON WILLEBRAND DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           VON WILLEBRAND DISEASE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           VON WILLEBRAND DISEASE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           LIFESTYLE CHANGES AND SELF CARE WITH VON WILLEBRAND DISEASE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           VON WILLEBRAND DISEASE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f5_55_6003="Dissection of the abdominal aorta on longitudinal ultrasound";
var content_f5_55_6003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81130%7ECARD%2F60665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81130%7ECARD%2F60665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the abdominal aorta on longitudinal ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis view shows a dissection of the abdominal aorta (AAo) and the presence of a spiral flap (f).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dissection of the abdominal aorta on transverse ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view shows a dissection (Dis) of the abdominal aorta (AoAb) and a spiral flap (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6003=[""].join("\n");
var outline_f5_55_6003=null;
var title_f5_55_6004="Fosaprepitant (intravenous aprepitant): Patient drug information";
var content_f5_55_6004=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fosaprepitant (intravenous aprepitant): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=see_link\">",
"     see \"Fosaprepitant (intravenous aprepitant): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/40/2695?source=see_link\">",
"     see \"Fosaprepitant (intravenous aprepitant): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5634805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg; for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12822224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg; IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691478",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop upset stomach and throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fosaprepitant, aprepitant, polysorbate 80, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698131",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hiccups.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To stop upset stomach from chemo, you will be given this drug 30 minutes before chemo.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12023 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6004=[""].join("\n");
var outline_f5_55_6004=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5634805\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12822224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019402\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019404\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019403\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019408\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019409\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019411\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019406\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019413\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=related_link\">",
"      Fosaprepitant (intravenous aprepitant): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/40/2695?source=related_link\">",
"      Fosaprepitant (intravenous aprepitant): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_55_6005="Dihydrocodeine, aspirin, and caffeine: Patient drug information";
var content_f5_55_6005=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dihydrocodeine, aspirin, and caffeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36359?source=see_link\">",
"     see \"Dihydrocodeine, aspirin, and caffeine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synalgos&reg;-DC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701951",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dihydrocodeine, aspirin, caffeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12199 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6005=[""].join("\n");
var outline_f5_55_6005=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160297\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025552\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025554\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025553\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025558\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025559\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025561\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025556\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025557\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025562\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025563\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36359?source=related_link\">",
"      Dihydrocodeine, aspirin, and caffeine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_55_6006="Fecal incontinence";
var content_f5_55_6006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Fecal incontinence (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6006/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6006/contributors\">",
"     Anthony J Lembo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6006/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6006/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6006/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6006/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/55/6006/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     FECAL INCONTINENCE OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fecal incontinence refers to the involuntary loss of gas or liquid stool (called minor incontinence) or the involuntary loss of solid stool (called major incontinence). Surveys indicate that it affects between 2 and 7 percent of the general population, although the true incidence may be much higher since many people are hesitant to discuss this problem with a healthcare provider.",
"   </p>",
"   <p>",
"    Minor fecal incontinence affects men and women equally, but women are almost twice as likely as men to report major incontinence. Fecal incontinence is also more common in older adults. It is particularly common in nursing home residents: studies suggest that almost half of all residents are incontinent.",
"   </p>",
"   <p>",
"    Fecal incontinence can undermine self-confidence, create anxiety, and lead to social isolation. People who suffer with fecal incontinence should learn as much as possible about their condition and discuss their symptoms honestly with their clinician. Fecal incontinence is a treatable condition; treatment can lessen symptoms in most cases and can often completely cure incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FECAL INCONTINENCE CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continence requires the normal function of both the lower digestive tract and the nervous system. The anal sphincters, along with the pelvic muscles that surround the end of the digestive tract, ensure controlled movement of digestive tract contents. There are many possible causes of fecal incontinence; in most cases, incontinence results from some combination of these causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Damage to the anal sphincters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The internal and external anal sphincters are the muscles located at the end of the rectum (",
"    <a class=\"graphic graphic_figure graphicRef56581 \" href=\"UTD.htm?14/56/15236\">",
"     figure 1",
"    </a>",
"    ). These muscles and the surrounding pelvic muscles create a barrier that prevents the escape of feces. Any damage to or loss of control over these sphincters can lead to incontinence. Damage most commonly occurs during vaginal childbirth and anal surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurologic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic disorders such as diabetes, multiple sclerosis, and spinal cord injury can decrease sensation and control over the lower digestive tract. Nerve damage during vaginal childbirth can also decrease anal sphincter function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Decreased distensibility of the rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions such as inflammatory bowel disease (eg, Crohn's disease and ulcerative colitis) and radiation-induced inflammation of the rectum (radiation proctitis) can impair the rectum's ability to expand and store fecal matter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fecal impaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hardened feces accumulates in the rectum, this can cause the anal sphincters to relax and allow liquid stool to escape around the blockage. Fecal impaction is a common cause of incontinence in older adults. Factors that make impaction more likely include certain mental health conditions, immobility, and loss of rectal sensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea of various causes, including irritable bowel syndrome, active inflammatory bowel disease, or acute gastroenteritis, can lead to loss of liquid stool. In some cases, if the diarrhea is treated, the person will be able to control their incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Unknown causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, the cause of fecal incontinence cannot be identified; this is called idiopathic incontinence. Idiopathic incontinence most commonly occurs in middle-aged and older women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FECAL INCONTINENCE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of fecal incontinence can often be established with a combination of a medical history, a physical examination, and diagnostic tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tests are particularly useful in pinpointing the cause and ensuring the correct treatment. One or more tests may be recommended, based upon the suspected cause(s) of incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Direct examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy (examination of the entire colon), sigmoidoscopy (examination of the terminal part of the colon), or anoscopy (examination of the anal canal) may be recommended. These tests can help identify inflammation, tumors, and other disorders that can cause fecal incontinence. Colonoscopy and sigmoidoscopy are discussed in detail in separate topic reviews. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"     \"Patient information: Colonoscopy (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"     \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Anorectal manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal manometry measures the internal pressure in different areas of the lower digestive tract under different conditions. This test can identify several of the different causes of incontinence and may be especially useful in revealing poor tone of the anal sphincters. Manometry can also be used to determine if rectal sensation and rectal reflexes are impaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ultrasound or MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ultrasound or magnetic resonance imaging (MRI) examination of the rectum can reveal abnormalities of the anal sphincters, the rectal wall, and the pelvic muscles that help maintain continence. These tests are generally safe and reliable for identifying structural abnormalities of both the internal and external anal sphincters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stool tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool testing may be done to determine if there is an underlying reason for diarrhea (eg, infection).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FECAL INCONTINENCE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three types of treatment are commonly used for fecal incontinence: medical therapy, biofeedback, and surgery. The specific treatment(s) recommended will depend upon the underlying cause of fecal incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy includes medication and certain measures that can reduce the frequency of incontinence and firm the stools, which can reduce or eliminate episodes of fecal leakage.",
"   </p>",
"   <p>",
"    Often, basic measures will improve minor incontinence, but more aggressive measures may be needed to control frequent or severe episodes of leakage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bulking substances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substances that promote bulkier stools may help control diarrhea by thickening the stools.",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?14/14/14564?source=see_link\">",
"     Methylcellulose",
"    </a>",
"    (a form of fiber) is one type of bulking substance that is commonly used. Increasing dietary fiber may also help to bulk stools (",
"    <a class=\"graphic graphic_table graphicRef52349 \" href=\"UTD.htm?28/61/29661\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"     Patient information: Constipation in adults (Beyond the Basics)",
"    </a>",
"    for further information on stool bulking).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Medications that reduce stool frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of stools can be reduced with medications that are usually prescribed for diarrhea, such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"     loperamide",
"    </a>",
"    (Imodium&reg;) and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?11/39/11892?source=see_link\">",
"     diphenoxylate",
"    </a>",
"    (Lomotil&reg;). Loperamide can also increase the tone (tightness) of the anal sphincter muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Anticholinergic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;When taken before meals, anticholinergic medications (such as the prescription drug",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39877?source=see_link\">",
"     hyoscyamine",
"    </a>",
"    ) can decrease the incontinence that occurs after meals in some people. The medications work by reducing contractions in the colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Treatment of impaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;People who have become impacted (when the rectum is full of hard stool) may need to have this stool removed in the office. After disimpaction, the person will be given one or more medications to keep the bowels moving on a regular basis. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"     \"Patient information: Constipation in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Defecation programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;When incontinence is related to a disability or mental health condition, a clinician will often recommend a scheduled toileting program. This usually involves sitting on the toilet at a regular time every day, after a meal. Incontinence is less likely to occur if the person empties their bowels regularly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Biofeedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofeedback is a safe and noninvasive way of retraining muscles. During biofeedback training, sensors are used to help the person to identify and contract the anal sphincter muscles, which help maintain continence. This is usually done in a healthcare provider or physical therapist's office.",
"   </p>",
"   <p>",
"    Biofeedback can be successful, although not all studies have confirmed a benefit. The people most likely to benefit from this type of therapy are people who can contract the anal sphincter muscle and have some sensation when they need to have a bowel movement. The effects of biofeedback may begin to decline six months after the initial training, and retraining may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201724295\">",
"    <span class=\"h2\">",
"     Sacral nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical stimulation can eliminate leakage in 40 to 75 percent of people whose anal sphincter muscles are intact [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6006/abstract/1\">",
"     1",
"    </a>",
"    ]. An electrode is surgically inserted near a nerve in the sacrum (low back) (",
"    <a class=\"graphic graphic_figure graphicRef60564 \" href=\"UTD.htm?14/50/15143\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is not entirely clear how sacral nerve stimulation works. Experience with this approach is limited. Some people develop complications of the surgery, including pain, device malfunction, or infection, which may require that the device is removed or replaced. At present, this treatment is generally reserved for people with an intact or repaired anal sphincter who have not improved with other treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201724302\">",
"    <span class=\"h2\">",
"     Anal electrical stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical stimulation involves using a mild electrical current to stimulate the anal sphincter muscles to contract, which can strengthen the muscles over time. The electrical current is applied using a small probe, which the patient inserts inside the rectum for a few minutes every day for 8 to 12 weeks.",
"   </p>",
"   <p>",
"    A controlled trial suggested that electrical stimulation has only a modest benefit, possibly from increasing sensation in the anal area. However, this treatment is inexpensive, non-invasive, and has few to no side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113329458\">",
"    <span class=\"h2\">",
"     Injectable bulking agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gel is injected into the anal sphincter just below the lining that may help build tissue in the anal canal, thereby narrowing the opening of the anus and allowing the patient to better control their anal sphincter. This device was approved the US Food and Drug Administration for clinical use in 2011 in patients ages 18 and up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different surgical procedures can help alleviate fecal incontinence. Surgical repair can reduce or resolve incontinence, particularly for women who develop a tear in the external anal sphincter during childbirth and in people with injury of the sphincter due to surgery or other causes. Surgery cures fecal incontinence in 80 percent of women with childbirth-related sphincter tears.",
"   </p>",
"   <p>",
"    In people who have irreparable damage of the sphincters, muscles can be transferred from other areas of the body, usually the leg or buttock, and surgically placed around the anal canal. These muscles mimic the action of the damaged sphincters. Muscle transfer surgery can restore continence in up to 73 percent of people.",
"   </p>",
"   <p>",
"    An alternative to a transferred muscle is a synthetic anal cuff that can be inflated to hold back feces and deflated to allow bowel movements. However, this type of procedure is only performed in specialized centers. Complications can occur even in when these surgeries are performed by experts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Colostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colostomy is a surgical procedure in which the colon is surgically attached to the abdominal wall. Stool is collected in a bag that fits snugly against the skin. This eliminates leakage of stool from the rectum. Variations on the procedure may allow the person to control bowel emptying.",
"   </p>",
"   <p>",
"    Colostomy is usually a last resort, after other treatments have failed. It may also be considered for people with intolerable symptoms who are not candidates for any other therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     REDUCING FECAL INCONTINENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some steps that patients can take to help minimize leakage of stool.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid foods and drinks that may cause loose or more frequent stools, which can worsen fecal incontinence. These can include dairy products (for people who are lactose intolerant), spicy foods, fatty or greasy foods, caffeinated beverages, diet foods or drinks, sugar-free gum or candy, and alcohol.",
"     </li>",
"     <li>",
"      Eat smaller more frequent meals. In some people, eating a large meal triggers the urge to have a bowel movement, and sometimes cause diarrhea. Eating smaller and more frequent meals can reduce the frequency of bowel movements.",
"     </li>",
"     <li>",
"      Increase fiber in the diet. Fiber increases stool bulk and often improves the consistency of stool. The recommend daily intake of fiber is 25 to 30 grams. The amount of fiber should be increased gradually over a few weeks to reduce the possibility of bloating and gas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2287305139\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11735613\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?37/50/38690?source=see_link\">",
"     Patient information: Fecal incontinence (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"     Patient information: High-fiber diet (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?26/60/27586?source=see_link\">",
"     Patient information: Rectal prolapse in adults (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11735643\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"     Patient information: Colonoscopy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"     Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"     Patient information: Constipation in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=see_link\">",
"     Delayed surgical management of the disrupted anal sphincter",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21735?source=see_link\">",
"     Endorectal endoscopic ultrasound in the evaluation of fecal incontinence",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link\">",
"     Fecal incontinence in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link\">",
"     Fecal incontinence related to pregnancy and vaginal delivery",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     Pelvic floor disorders associated with pregnancy and childbirth",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=see_link\">",
"     Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11799?source=see_link\">",
"     Reconstructive materials used in surgery: Classification and host response",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link\">",
"     Rectovaginal, anovaginal, and colovesical fistulas",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"     www.nlm.nih.gov/medlineplus/healthtopics.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute on Diabetes and Digestive and Kidney Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"     www.niddk.nih.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Society of Colon and Rectal Surgeons",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.fascrs.org/\">",
"     www.fascrs.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6006/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/1\">",
"      Jarrett ME, Mowatt G, Glazener CM, et al. Systematic review of sacral nerve stimulation for faecal incontinence and constipation. Br J Surg 2004; 91:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/2\">",
"      Barnett JL, Hasler WL, Camilleri M. American Gastroenterological Association medical position statement on anorectal testing techniques. American Gastroenterological Association. Gastroenterology 1999; 116:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/3\">",
"      Christiansen J. Modern surgical treatment of anal incontinence. Ann Med 1998; 30:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/4\">",
"      Kamm MA. Faecal incontinence. BMJ 1998; 316:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/5\">",
"      Keating JP, Stewart PJ, Eyers AA, et al. Are special investigations of value in the management of patients with fecal incontinence? Dis Colon Rectum 1997; 40:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/6\">",
"      Ko CY, Tong J, Lehman RE, et al. Biofeedback is effective therapy for fecal incontinence and constipation. Arch Surg 1997; 132:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/7\">",
"      Madoff RD, Williams JG, Caushaj PF. Fecal incontinence. N Engl J Med 1992; 326:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6006/abstract/8\">",
"      Rao SS, American College of Gastroenterology Practice Parameters Committee. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 2004; 99:1585.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2007 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6006=[""].join("\n");
var outline_f5_55_6006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      FECAL INCONTINENCE OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FECAL INCONTINENCE CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Damage to the anal sphincters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurologic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Decreased distensibility of the rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fecal impaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unknown causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FECAL INCONTINENCE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Direct examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Anorectal manometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ultrasound or MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stool tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FECAL INCONTINENCE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bulking substances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Medications that reduce stool frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Anticholinergic medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Treatment of impaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Defecation programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Biofeedback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H201724295\">",
"      Sacral nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H201724302\">",
"      Anal electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H113329458\">",
"      Injectable bulking agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Colostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      REDUCING FECAL INCONTINENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2287305139\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11735613\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11735643\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/2007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/2007|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/56/15236\" title=\"figure 1\">",
"      Anal sphincter anatomy PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/50/15143\" title=\"figure 2\">",
"      Sacral neuromodulation PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/2007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\" title=\"table 1\">",
"      Fiber in foods PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34263?source=related_link\">",
"      Delayed surgical management of the disrupted anal sphincter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21735?source=related_link\">",
"      Endorectal endoscopic ultrasound in the evaluation of fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/62/26602?source=related_link\">",
"      Overview of transvaginal placement of reconstructive materials (surgical mesh or biografts) for treatment of pelvic organ prolapse or stress urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=related_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/50/38690?source=related_link\">",
"      Patient information: Fecal incontinence (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=related_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/60/27586?source=related_link\">",
"      Patient information: Rectal prolapse in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/33/11799?source=related_link\">",
"      Reconstructive materials used in surgery: Classification and host response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_55_6007="Evaluation and prognosis of Eisenmenger syndrome";
var content_f5_55_6007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and prognosis of Eisenmenger syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6007/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6007/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6007/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6007/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6007/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6007/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/55/6007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1897, Eisenmenger described a syndrome in which pulmonary vascular disease developed in patients with a nonrestrictive ventricular septal defect (",
"    <a class=\"graphic graphic_figure graphicRef52487 graphicRef70502 \" href=\"UTD.htm?41/28/42441\">",
"     figure 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/1\">",
"     1",
"    </a>",
"    ]. It was subsequently shown that pulmonary vascular disease could also occur with other congenital cardiac defects in which a systemic-to-pulmonary communication is present such as atrial shunts, other ventricular shunts, and aortic shunts (",
"    <a class=\"graphic graphic_table graphicRef55944 \" href=\"UTD.htm?37/8/38027\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Such conditions are often associated with an initial left-to-right shunt. Increased pulmonary blood flow as a result of the shunt leads to the development of pulmonary vascular disease with increased pulmonary vascular resistance. The shunt may then reverse and become right-to-left (",
"    <a class=\"graphic graphic_figure graphicRef52487 graphicRef70502 \" href=\"UTD.htm?41/28/42441\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef58708 \" href=\"UTD.htm?10/55/11133\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. At this stage, the patient typically becomes cyanotic.",
"   </p>",
"   <p>",
"    The triad of systemic-to-pulmonary cardiovascular communication, pulmonary arterial disease and cyanosis is called Eisenmenger syndrome. The diagnosis of Eisenmenger syndrome implies that pulmonary arterial disease has developed as a consequence of increased pulmonary blood flow, and requires exclusion of other causes of pulmonary hypertension.",
"   </p>",
"   <p>",
"    With the advent of surgical correction of congenital heart disease (CHD), the prevalence of Eisenmenger syndrome has declined but is not negligible. This topic will review the general features, evaluation, and prognosis of CHD-related pulmonary arterial hypertension and Eisenmenger syndrome. The pathology and pathophysiology of pulmonary hypertension in Eisenmenger syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The medical management of patients with Eisenmenger syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link\">",
"     \"Medical management of Eisenmenger syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Eisenmenger syndrome requires the presence of congenital heart disease. In some cases, the diagnosis is not established until adulthood, after the development of symptoms or even overt signs of pulmonary hypertension such as syncope, atrial and ventricular arrhythmias, and as late findings, both right and left heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anatomy and physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of Eisenmenger syndrome may accompany a variety of forms of congenital heart disease (CHD). In one study of 201 patients, the most common defects were ventricular septal defects (33 percent), atrial septal defects (30 percent), and patent ductus arteriosus (14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/4\">",
"     4",
"    </a>",
"    ]. Other disorders, including complex anatomic abnormalities, can also be associated with the Eisenmenger syndrome. In all cases, a communication between the systemic and pulmonary circulations is present. In some conditions, the normal anatomic relations between the atria, ventricles, and great vessels may be altered. For simplicity, in the discussions that follow, the term \"right ventricle\" will be used to describe the ventricle from which the main pulmonary artery arises; the term \"left ventricle\" will be used to describe the ventricle from which the aorta arises.",
"   </p>",
"   <p>",
"    Systemic-to-pulmonary communications usually do not have major effects on fetal blood flow pathways. Right-to-left shunting at the atrial level (across the foramen ovale) is normal in utero, and the high pulmonary vascular resistance of the fetus limits left-to-right shunting. In the postnatal period, there is a rapid decline in pulmonary vascular resistance and an increase in right ventricular compliance, resulting in a left-to-right shunt and an increase in pulmonary blood flow.",
"   </p>",
"   <p>",
"    In most patients with systemic-to-pulmonary communications, shunting occurs to some degree in both directions. This is not surprising since, during the cardiac cycle, there are changes in intrathoracic pressure associated with respiration, and changes in venous return associated with exercise, changes in position, and other factors. As a result, the pressure gradient across such communications varies with time. The convention of referring to a shunt as \"left-to-right\" or \"right-to-left\" is therefore typically an expression of the",
"    <strong>",
"     net",
"    </strong>",
"    result of bidirectional shunting.",
"   </p>",
"   <p>",
"    The extent of extra flow is assessed as the ratio of measured pulmonary blood flow (Qp) to systemic blood flow (Qs). In the normal case, where no connection exists, the ratio Qp:Qs is 1:1. Net left-to-right shunting results in a Qp:Qs &gt;1, while net right-to-left shunting results in a Qp:Qs &lt;1. For example, a Qp:Qs of 2:1 indicates that the pulmonary blood flow is twice that of systemic blood flow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=see_link\">",
"     \"Pathophysiology of left to right shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in pulmonary blood flow with net left-to-right shunting eventually leads to pulmonary vascular disease (",
"    <a class=\"graphic graphic_picture graphicRef64141 \" href=\"UTD.htm?12/62/13283\">",
"     picture 1",
"    </a>",
"    ) and increased pulmonary vascular resistance. The increase in pulmonary vascular resistance results in a rise in pulmonary artery pressure which is called \"pulmonary arteriolar hypertension\" (PAH) to emphasize the etiologic influence of disease in the pulmonary arterioles. Pulmonary arteriolar hypertension causes reversal of the shunt and net right-to-left shunting (Qp:Qs &lt;1) (",
"    <a class=\"graphic graphic_algorithm graphicRef58708 \" href=\"UTD.htm?10/55/11133\">",
"     algorithm 1",
"    </a>",
"    ). With shunt reversal, venous blood returning to the right side of the heart passes through the communication, reducing the oxygen saturation of the arterial blood in the left heart and causing cyanosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Shunt size and defect type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing the Eisenmenger syndrome appears to be determined by the size of the initial left-to-right shunt and the volume of pulmonary blood flow, with larger shunts having increased risk. In addition, however, the type of defect is important. Only about 10 percent of patients with unrepaired atrial septal defects develop the Eisenmenger syndrome, compared to 50 percent of patients with unrepaired ventricular septal defects and nearly all patients with unrepaired truncus arteriosus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Eisenmenger syndrome has been documented in some patients who never manifested a large left-to-right shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In fact, it is unusual for the evolution of the syndrome to be documented clinically (especially given the currently available approaches to managing known left-to-right shunts). The temporal pathophysiologic sequence outlined above (",
"    <a class=\"graphic graphic_algorithm graphicRef58708 \" href=\"UTD.htm?10/55/11133\">",
"     algorithm 1",
"    </a>",
"    ) has therefore been called into question; in most patients diagnosed with Eisenmenger syndrome, PAH, right-to-left shunting and cyanosis are found at initial presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination of the patient with Eisenmenger syndrome demonstrates central cyanosis and digital clubbing (",
"    <a class=\"graphic graphic_figure graphicRef52839 \" href=\"UTD.htm?42/58/43951\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77116 \" href=\"UTD.htm?33/23/34174\">",
"     picture 2",
"    </a>",
"    ). Most patients have diffuse central cyanosis, and clubbing involves all extremities equally. However, in some cases the pattern and degree of cyanosis and clubbing may depend upon the patient's hemodynamic status and the cardiac anatomy. An often discussed example is the patient with a patent ductus arteriosus and Eisenmenger syndrome, in whom the right-to-left shunt through the ductus typically delivers unoxygenated blood distal to the left subclavian artery. This can result in differential cyanosis and clubbing that may be more pronounced in the lower extremities.",
"   </p>",
"   <p>",
"    The cardiovascular examination reveals findings consistent with the presence of PAH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early physical signs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The jugular venous pulse is usually normal when the shunt is distal to the tricuspid valve. In other cases, a prominent \"a\" wave is seen, due to right atrial contraction that generates a high pressure in order to fill the dilated and hypertrophied right ventricle (",
"      <a class=\"graphic graphic_figure graphicRef81625 \" href=\"UTD.htm?19/16/19727\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A right ventricular impulse and a palpable pulmonary closure sound (P2) are commonly found on precordial palpation.",
"     </li>",
"     <li>",
"      There is usually no murmur, but an ejection sound is common due to dilatation of the pulmonary artery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With progressive right heart failure, the following changes become apparent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean jugular venous pressure increases, as does the magnitude of the a wave. With the development of tricuspid regurgitation, the v wave also increases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The increase in venous pressure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurohormonal activation can lead to peripheral edema, hepatomegaly, and ascites [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Murmurs of tricuspid and pulmonic regurgitation become audible. Tricuspid regurgitation in this setting is secondary to dilatation of the tricuspid annulus and right ventricle, and is not a sign of valve disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=see_link\">",
"       \"Etiology, clinical features, and evaluation of tricuspid regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean age at death of patients with Eisenmenger physiology has been reported to be 37 years, although the individual clinical course is quite variable. Most patients are thought to die from progressive cardiovascular disease and heart failure, from sudden cardiac death, or from intrapulmonary hemorrhage due to rupture of a major vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival of patients into their 60s has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 188 Eisenmenger patients found that those with complex congenital heart disease had earlier clinical deterioration (mean age 19 versus 27 years) and shorter survival (mean age 26 versus 33 years) than those with simple congenital heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/12\">",
"       12",
"      </a>",
"      ]. Hemoptysis, which occurred in 20 percent of patients, did not affect prognosis.",
"     </li>",
"     <li>",
"      A later series of 171 Eisenmenger patients found that median survival was reduced by about 20 years in those with simple underlying lesions and by about 40 years in those with complex lesions compared to healthy individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/14\">",
"       14",
"      </a>",
"      ]. Predictors of mortality included functional class, signs of heart failure, history of clinical arrhythmias, QRS duration and QTc interval, low serum albumin, and low potassium levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eisenmenger patients have a better life expectancy than patients with primary pulmonary hypertension (PPH) who have similar hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This was illustrated in a report of patients with severe PAH (37 Eisenmenger, 57 PPH) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/15\">",
"     15",
"    </a>",
"    ]. Actuarial survival at one and three years of those not receiving transplants was higher in those with Eisenmenger syndrome (97 versus 77 percent and 77 versus 35 percent, respectively). This difference may be related, in part, to the preservation of biventricular function in Eisenmenger patients, with the potential for biventricular sharing of the hemodynamic loading conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION FOR CONGENITAL HEART DISEASE RELATED PULMONARY ARTERIAL HYPERTENSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended the following noninvasive assessment in all adult congenital heart disease (CHD) patients with suspected pulmonary artery hypertension (PAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulse oximetry, with and without administration of supplemental oxygen, as appropriate. Finger and toe oximetry in those with suspected Eisenmenger syndrome.",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG). The ECG may demonstrate right or biventricular hypertrophy with associated ST-T wave changes (",
"      <a class=\"graphic graphic_waveform graphicRef67622 \" href=\"UTD.htm?43/21/44378\">",
"       waveform 1",
"      </a>",
"      ). There may also be evidence of a right atrial abnormality (a tall, narrow P wave) (",
"      <a class=\"graphic graphic_waveform graphicRef64928 \" href=\"UTD.htm?5/28/5575\">",
"       waveform 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef78126 \" href=\"UTD.htm?22/59/23472\">",
"       waveform 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=see_link\">",
"       \"ECG tutorial: Chamber enlargement and hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest x-ray. The chest x-ray usually shows dilatation of the central pulmonary arteries, peripheral pulmonary artery \"pruning\" (abrupt attenuation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      termination of peripheral pulmonary artery branches), neovascularity, which is better seen on CT scan [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/19\">",
"       19",
"      </a>",
"      ], and right heart enlargement (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74023 \" href=\"UTD.htm?12/11/12468\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Complete blood count and nuclear lung scintigraphy",
"     </li>",
"     <li>",
"      Cardiovascular imaging via transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), cardiovascular magnetic resonance imaging (CMRI), or computed tomography (CT).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Imaging findings can include signs of chronic right ventricular pressure overload. The elevation in pressure leads to increased right ventricular wall thickness with paradoxical bulging of the septum into the left ventricle during systole (",
"      <a class=\"graphic graphic_figure graphicRef77640 \" href=\"UTD.htm?39/52/40782\">",
"       figure 4",
"      </a>",
"      ). With more advanced disease, right ventricular dilatation and hypokinesis occur, the septum shows abnormal diastolic flattening, and right atrial dilatation and tricuspid and pulmonic regurgitation are seen (",
"      <a class=\"graphic graphic_movie graphicRef55501 \" href=\"UTD.htm?9/18/9506\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef67911 \" href=\"UTD.htm?19/59/20402\">",
"       movie 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Imaging also may demonstrate the underlying cardiac defect responsible for the initial left-to-right shunt (",
"      <a class=\"graphic graphic_movie graphicRef80448 \" href=\"UTD.htm?6/56/7040\">",
"       movie 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef79348 \" href=\"UTD.htm?22/39/23167\">",
"       movie 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef57768 \" href=\"UTD.htm?3/6/3171\">",
"       movie 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef57251 \" href=\"UTD.htm?17/39/18047\">",
"       movie 6",
"      </a>",
"      ). Delineation of the cardiac defect may be difficult with transthoracic echocardiography due to equalization of pressures in the right and left heart.",
"     </li>",
"     <li>",
"      Two dimensional echocardiography may be limited by poor acoustic windows in patients with PAH. Additional noninvasive imaging or transesophageal echocardiography should be considered in patients presenting with PAH in an effort to exclude congenital heart disease. Transesophageal echocardiography may be contraindicated in some patients given the potential risk of sedation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link&amp;anchor=H18#H18\">",
"       \"Medical management of Eisenmenger syndrome\", section on 'Noncardiac surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Computed tomography (CT) and CT angiography of the pulmonary arteries can reveal enlargement, thrombosis, and mural calcification of the pulmonary trunk and its proximal branches [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Within the lung parenchyma, embolic infarction, hemorrhage, neovascularity, lobular ground glass opacification, and hilar and intercostal collaterals may also be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/19\">",
"       19",
"      </a>",
"      ]. The last three abnormalities appear to occur more frequently than in acyanotic pulmonary arterial hypertension and may correspond to the histologic findings of malformed, dilated muscular arteries within the alveolar septae, and congested capillaries within the walls of both alveoli and medium-sized pulmonary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/19\">",
"       19",
"      </a>",
"      ]. These lesions are more common and more severe with post-tricuspid right-to-left shunts at the level of the ventricles or great arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Additional testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If PAH is identified but its causes are not identified, additional testing should include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary function tests with volumes and diffusion capacity (diffusing capacity of the lung for carbon monoxide).",
"     </li>",
"     <li>",
"      Pulmonary embolism protocol CT with parenchymal lung windows.",
"     </li>",
"     <li>",
"      Additional testing as appropriate to rule out contributing causes of PAH. A 6 minute walk test or similar exercise test may be considered as part of the functional assessment.",
"     </li>",
"     <li>",
"      Cardiac catheterization at least once, with potential for vasodilator testing or anatomic intervention, at a center with expertise in catheterization, PAH, and management of CHD-PAH. Cardiac catheterization enables characterization of the cardiac shunt and determination of pulmonary vascular resistance and responsiveness to vasodilators. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"       \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are a multitude of factors that may confound the hemodynamic evaluation and quantification of PAH in the Eisenmenger syndrome, especially in patients with complex congenital heart disease. These may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary venous hypertension due to left atrial hypertension or atrioventricular valve regurgitation.",
"     </li>",
"     <li>",
"      Pulmonary venous obstruction.",
"     </li>",
"     <li>",
"      Pulmonary parenchymal disease or restrictive lung disease.",
"     </li>",
"     <li>",
"      In situ pulmonary artery thrombosis.",
"     </li>",
"     <li>",
"      Altered anatomic relations and hemodynamics that may impede routine catheter advancement and positioning.",
"     </li>",
"     <li>",
"      Pulmonary vascular resistance is flow dependent so PVR may not necessarily fall in proportion to the reduction in shunt and pulmonary blood flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Additional evaluation for suspected Eisenmenger syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of suspected Eisenmenger physiology includes a detailed history for all past medical and surgical interventions, thorough understanding of past and current anatomy, and evaluation of degree of PAH, ventricular function, and any secondary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation should include all the above initial and additional testing plus ferritin and iron studies, renal and hepatic function tests, and 6-minute walk testing.",
"   </p>",
"   <p>",
"    Lung biopsy is",
"    <strong>",
"     NOT",
"    </strong>",
"    routinely used in diagnosing Eisenmenger syndrome. However, when a biopsy is obtained, characteristic histologic features are seen (",
"    <a class=\"graphic graphic_picture graphicRef64141 \" href=\"UTD.htm?12/62/13283\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6007/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The histologic grading of pulmonary vascular disease in patients with congenital heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis of pulmonary hypertension\", section on 'Congenital heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eisenmenger syndrome is the triad of systemic-to-pulmonary cardiovascular communication, pulmonary arterial disease causing severe pulmonary hypertension, and cyanosis. The development of pulmonary arterial disease is a consequence of increased pulmonary blood flow, and requires exclusion of other causes of pulmonary hypertension.",
"     </li>",
"     <li>",
"      Physical examination of the patient with Eisenmenger syndrome generally demonstrates central cyanosis and digital clubbing. Common findings include a right ventricular impulse and a palpable pulmonary closure sound (P2).",
"     </li>",
"     <li>",
"      Life expectancy is generally more severely reduced in Eisenmenger patients with complex congenital heart disease than in Eisenmenger patients with simple lesions.",
"     </li>",
"     <li>",
"      Eisenmenger patients have a better life expectancy than patients with primary pulmonary hypertension (PPH) who have similar hemodynamics.",
"     </li>",
"     <li>",
"      Evaluation for congenital heart disease related pulmonary arterial hypertension should include noninvasive assessment of cardiopulmonary anatomy and function. If evaluation by cardiac catheterization is indicated, the procedure should be performed in a center with expertise in managing congenital heart disease related pulmonary arterial hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/1\">",
"      Eisenmenger, V. Die Angeboren Defect der Kammer scheiderwand des Herzens. Z Klin Med Suppl 1897; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/2\">",
"      WOOD P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I. Br Med J 1958; 2:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/3\">",
"      Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/4\">",
"      Saha A, Balakrishnan KG, Jaiswal PK, et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994; 45:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/5\">",
"      Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 2002; 20:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/6\">",
"      Blieden LC, Moller JH. Small ventricular septal defect associated with severe pulmonary hypertension. Br Heart J 1984; 52:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/7\">",
"      Bisset GS 3rd, Hirschfeld SS. Severe pulmonary hypertension associated with a small ventricular septal defect. Circulation 1983; 67:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/8\">",
"      Bolger AP, Sharma R, Li W, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002; 106:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/9\">",
"      Ohuchi H, Takasugi H, Ohashi H, et al. Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003; 108:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/10\">",
"      Mikami T, Kudo T, Sakurai N, et al. Mechanisms for development of functional tricuspid regurgitation determined by pulsed Doppler and two-dimensional echocardiography. Am J Cardiol 1984; 53:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/11\">",
"      Niwa K, Perloff JK, Kaplan S, et al. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/12\">",
"      Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/13\">",
"      Warnes CA, Boger JE, Roberts WC. Eisenmenger ventricular septal defect with prolonged survival. Am J Cardiol 1984; 54:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/14\">",
"      Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006; 27:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/15\">",
"      Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/16\">",
"      Hayden AM, Robert RC, Kriett JM, et al. Primary diagnosis predicts prognosis of lung transplant candidates. Transplantation 1993; 55:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/17\">",
"      Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002; 89:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/18\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/19\">",
"      Sheehan R, Perloff JK, Fishbein MC, et al. Pulmonary neovascularity: a distinctive radiographic finding in Eisenmenger syndrome. Circulation 2005; 112:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/20\">",
"      Perloff JK, Hart EM, Greaves SM, et al. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003; 92:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/21\">",
"      Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/22\">",
"      HEATH D, EDWARDS JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6007/abstract/23\">",
"      Rabinovitch M, Haworth SG, Castaneda AR, et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978; 58:1107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1414 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-189.41.172.26-9D38EAC1B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6007=[""].join("\n");
var outline_f5_55_6007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anatomy and physiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Shunt size and defect type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION FOR CONGENITAL HEART DISEASE RELATED PULMONARY ARTERIAL HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Additional testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Additional evaluation for suspected Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1414|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/55/11133\" title=\"algorithm 1\">",
"      Pathophysiology Eisenmenger",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1414|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/11/12468\" title=\"diagnostic image 1\">",
"      CXR of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1414|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/0/12290\" title=\"figure 1A\">",
"      Pathophysiology VSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/8/33927\" title=\"figure 1B\">",
"      Eisenmenger syndrome anatomy and physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/58/43951\" title=\"figure 2\">",
"      Clubbing of the fingers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/16/19727\" title=\"figure 3\">",
"      Eisenmenger heart specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/52/40782\" title=\"figure 4\">",
"      Schematic of echo findings in PH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1414|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/62/13283\" title=\"picture 1\">",
"      Intimal hyperplasia in PAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/23/34174\" title=\"picture 2\">",
"      Finger clubbing cyanosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1414|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?9/18/9506\" title=\"movie 1\">",
"      Pulmonary hypertension four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?19/59/20402\" title=\"movie 2\">",
"      Pulmonary hypertension short axis echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/56/7040\" title=\"movie 3\">",
"      TTE two ASDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?22/39/23167\" title=\"movie 4\">",
"      TEE ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?3/6/3171\" title=\"movie 5\">",
"      VSD short axis color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/39/18047\" title=\"movie 6\">",
"      VSD small four chamber color Doppler echo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1414|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/8/38027\" title=\"table 1\">",
"      Causes of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1414|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/21/44378\" title=\"waveform 1\">",
"      ECG of right ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/28/5575\" title=\"waveform 2\">",
"      ECG of atrial enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?22/59/23472\" title=\"waveform 3\">",
"      RA enlargement ECG tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27204?source=related_link\">",
"      ECG tutorial: Chamber enlargement and hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4344?source=related_link\">",
"      Pathophysiology of left to right shunts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_55_6008="Anterior view superficial veins of the upper extremity";
var content_f5_55_6008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55596%7ESURG%2F61941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55596%7ESURG%2F61941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior view superficial veins of the upper extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <ul>",
"     <li>",
"      The cephalic vein originates at the radial aspect of the wrist traversing the radial border of the forearm. It receives tributaries from both the ventral and dorsal surfaces. At the antecubital fossa it provides a tributary to the median cubital vein. In the upper arm, it travels in the groove between the pectoralis major and deltoid muscles. It pierces the coracoclavicular fascia and, crossing the axillary artery, ends in the axillary vein just below the clavicle. Sometimes it communicates with the external jugular vein by a branch which ascends anterior to the clavicle.",
"     </li>",
"     <li>",
"      The basilic vein originates in the ulnar aspect of the wrist traversing the ulnar side of the forearm to the antecubital fossa where it is joined by the median cubital vein. It ascends in the groove between the biceps brachii and pronator teres, crosses the brachial artery at the elbow and continues cephalad along the medial border of the biceps brachii. It perforates the deep fascia of the upper arm and joins the brachial vein.",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Deep veins of the upper extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 695px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The deep veins of the upper extremity include the paired ulnar, radial and interosseous veins in the forearm, paired brachial veins of the upper arm, and axillary vein. The axillary vein originates at the lower border of the teres major muscle in continuity with the brachial veins. The basilic and cephalic veins, which are superficial veins, contribute to the axillary vein, though many anatomic variations occur. After passing the outer margin of the first rib, the axillary vein continues as the subclavian vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6008=[""].join("\n");
var outline_f5_55_6008=null;
var title_f5_55_6009="Intraventricular hemorrhage";
var content_f5_55_6009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraventricular hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6009/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6009/contributors\">",
"     Brett L Cucchiara, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6009/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6009/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/55/6009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary intraventricular hemorrhage (IVH) refers to bleeding confined to the ventricular system within the brain. Primary IVH is uncommon, accounting for only about 3 percent of all spontaneous intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1\">",
"     1",
"    </a>",
"    ]. Intraventricular hemorrhage more commonly occurs in the setting of intracerebral hemorrhage or subarachnoid hemorrhage (secondary IVH).",
"   </p>",
"   <p>",
"    The assessment of the patient with IVH focuses on identifying the underlying cause of the hemorrhage, which may have significant treatment implications. The distinction between primary and secondary IVH is critical in this regard. Common to patients with IVH, regardless of etiology, is a risk for sudden and potentially fatal obstructive hydrocephalus, requiring acute clinical decision-making regarding the use of external ventricular drainage and other interventions.",
"   </p>",
"   <p>",
"    This topic discusses the causes, clinical presentation, diagnosis, and treatment of IVH. Intracerebral, subarachnoid, subdural, and epidural hemorrhage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=see_link\">",
"     \"Subdural hematoma in adults: Prognosis and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=see_link\">",
"     \"Intracranial epidural hematoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF PRIMARY IVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary IVH is uncommon, accounting for only about 3 percent of all spontaneous intracerebral hemorrhages [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1\">",
"     1",
"    </a>",
"    ]. The following demographic characteristics were reported in a 2008 review of published cases series of primary intraventricular hemorrhage (IVH) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The median age is 55 years (range 9 to 91 years)",
"     </li>",
"     <li>",
"      Males and females are equally represented",
"     </li>",
"     <li>",
"      Half of patients have a history of hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology of intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVH most commonly occurs as a secondary phenomenon when parenchymal or intracerebral hemorrhage (ICH) ruptures into the ventricular space or when subarachnoid hemorrhage (SAH) extends into the ventricles. IVH is estimated to complicate 40 percent of ICH and 10 percent of SAH cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one retrospective review,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy was associated with IVH risk, volume at presentation, and subsequent expansion in patients with deep or lobar ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/5\">",
"     5",
"    </a>",
"    ]. The underlying causes of ICH and SAH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IVH can also complicate closed head injury. Usually, this is in the setting of other traumatic brain injury, including contusion and traumatic SAH; isolated IVH is a relatively rare complication of head trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary IVH is uncommon; in consequence, studies estimating the frequency of various etiologies have been limited. Retrospective case series derived from tertiary referral centers are subject to ascertainment bias. Further, definitions of primary IVH have varied among different authors and studies. While most limit their use of the term to hemorrhages entirely localized within the ventricle, others have included hemorrhages that originate within 15 mm of the ependymal surface [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/9\">",
"     9",
"    </a>",
"    ]. The latter criteria invariably classify thalamic, caudate, and medial putaminal bleeds (usually secondary to chronic hypertension) associated with IVH as primary IVH.",
"   </p>",
"   <p>",
"    Among series which more strictly limit the definition of IVH, vascular malformations are the most frequently identified cause of primary IVH. In small case series, vascular malformations have been identified in 14 to 58 percent of patients with primary IVH [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2,9-14\">",
"     2,9-14",
"    </a>",
"    ]. Reported causes of IVH include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular malformations (usually arteriovenous malformations or arteriovenous fistulae) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1,2,9-18\">",
"       1,2,9-18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intraventricular tumors (papilloma, neurocytoma, meningioma, metastases, astrocytoma, ependymoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/10,19-25\">",
"       10,19-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intraventricular aneurysms developing within the distal lenticulostriate or choroidal arteries (occasionally reported in association with Moyamoya disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/9,15,21,26\">",
"       9,15,21,26",
"      </a>",
"      ]. Occasionally aneurysms of the anterior communicating artery, posterior inferior cerebellar artery, or basilar tip rupture into the ventricles without other overt subarachnoid blood [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2,9,13\">",
"       2,9,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Moyamoya disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1,2,15,21,27,28\">",
"       1,2,15,21,27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=see_link\">",
"       \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coagulopathies, acquired or inherited [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2,9,11,28-30\">",
"       2,9,11,28-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pituitary apoplexy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sympathomimetic abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In approximately 20 to 50 percent of cases (depending in part on the intensity of the investigation), no cause is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/10,11,15,30\">",
"     10,11,15,30",
"    </a>",
"    ]. About half of these patients have chronic hypertension; this is believed, but not known, to cause IVH in the same way it is understood to cause ICH. It is speculated that some patients with IVH may have had a small hypertensive intraparenchymal hemorrhage, too small to see on CT or MRI, which arises in proximity to the ventricular system and produces IVH as its primary manifestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H2#H2\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with secondary IVH present with clinical features typical of ICH or SAH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with primary IVH typically present with abrupt headache, often associated with nausea, vomiting, and impaired consciousness (confusion, disorientation) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2,10,30,35\">",
"     2,10,30,35",
"    </a>",
"    ]. A minority of patients have frank loss of consciousness at the onset [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/11\">",
"     11",
"    </a>",
"    ]. Symptoms are usually sudden in onset; however, nearly a quarter of patients are reported to have progressive or fluctuating symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The degree of neurologic impairment, often measured as the Glasgow coma scale (GCS) (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ) is an important prognostic indicator (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Prognosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Focal neurologic findings are relatively uncommon with primary IVH and most typically involve cranial nerve abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/9\">",
"     9",
"    </a>",
"    ]. Such cranial nerve palsies are generally of the \"false localizing\" type due to stretching across the basilar skull surface, and include dysfunction of the sixth and third nerves. Seizures are not common, but can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1,9,10,16\">",
"     1,9,10,16",
"    </a>",
"    ]. Most patients are hypertensive on presentation, and some will have an elevated body temperature or suffer cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/11\">",
"     11",
"    </a>",
"    ]. Nuchal rigidity is inconsistently present.",
"   </p>",
"   <p>",
"    The clinical symptoms and signs of IVH reflect a sudden increase in intracranial pressure (ICP) that results from sudden introduction of blood volume into the intracranial space [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition to pressure effects, it is speculated that blood products in the cerebrospinal fluid space may affect brain function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IVH are at risk for sudden neurologic deterioration which may result from obstructive hydrocephalus, recurrent hemorrhage or other complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute obstructive hydrocephalus can result when cerebrospinal fluid circulation is obstructed by blood clots. Patients with blood in the third or fourth ventricle are at most risk of this complication [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/11\">",
"       11",
"      </a>",
"      ]. One-half to two-thirds of patients with IVH have some degree of hydrocephalus on the initial CT scan [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2,10,11,14,37\">",
"       2,10,11,14,37",
"      </a>",
"      ]. This can be rapidly fatal and usually requires urgent intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/7,36\">",
"       7,36",
"      </a>",
"      ]. Patients may also develop communicating hydrocephalus as a delayed complication of IVH; this usually presents more gradually. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Recurrent hemorrhage or hemorrhage extension occurs in 10 to 20 percent of patients with IVH [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/11,36\">",
"       11,36",
"      </a>",
"      ]. The highest risk of this is in those with an underlying etiology of vascular malformation or aneurysm or in the setting of a coagulopathy.",
"     </li>",
"     <li>",
"      Cerebral vasospasm with ischemia is unusual in cases of primary IVH, but this complication has been described in isolated cases [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/18,38,39\">",
"       18,38,39",
"      </a>",
"      ]. In contrast, vasospasm is a common complication of aneurysmal SAH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical complications are common in the setting of IVH and may manifest primarily as neurologic deterioration. These include pulmonary embolism, pneumonia and other infections, and electrolyte imbalance. Other medical complications of IVH include cardiovascular instability, deep venous thrombosis, and gastrointestinal bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of primary IVH overlaps with those of aneurysmal SAH, which because of its implications for urgent diagnostic and therapeutic interventions should be immediately excluded with emergent CT scan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other etiologies of a headache with sudden onset include cerebral venous thrombosis, cerebral hemorrhage, and ischemic stroke, among others (",
"    <a class=\"graphic graphic_table graphicRef81710 \" href=\"UTD.htm?30/1/30747\">",
"     table 2",
"    </a>",
"    ). A noncontrast head CT will distinguish IVH from these other entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link&amp;anchor=H2#H2\">",
"     \"Thunderclap headache\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-contrast head CT is the test of choice to diagnose IVH. CT rapidly and reliably identifies blood within the ventricular system, helps to identify parenchymal ICH or SAH associated with the IVH, and also identifies concurrent hydrocephalus.",
"   </p>",
"   <p>",
"    In patients with suspected primary IVH, close examination of the brain regions surrounding the ventricles (caudate and thalamus, in particular) should be undertaken to exclude an ICH that has ruptured into the ventricles. If present, the diagnostic evaluation for ICH should be pursued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .) Similarly, the presence of subarachnoid blood in the basal cisterns or cortical sulci should raise concern for aneurysmal SAH with secondary IVH, and the diagnostic evaluation should be modified accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extent of IVH can be graded by CT. The most commonly applied scoring system is the Graeb score (GS) which grades IVH on a scale of 1 to 12 based upon the extent of bleeding and the presence of ventricular enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/40\">",
"     40",
"    </a>",
"    ]. Other scoring systems for IVH have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/41\">",
"     41",
"    </a>",
"    ]. While these may more accurately quantify the amount of IVH; they are more complicated to use and are not widely implemented. The GS correlates with level of consciousness, Glasgow coma scale, and also has implications for outcome (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Prognosis'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/11,37\">",
"     11,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CT scan should be repeated emergently for any neurologic deterioration to identify recurrent hemorrhage or obstructive hydrocephalus. CT scans are also used to monitor hydrocephalus, particularly during attempts to clamp or remove a drain. Transcranial ultrasonography has been suggested as a possible alternative to serial CT to monitor ventricular size, but the reliability and reproducibility of this technique has yet to be independently validated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other neuroimaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neuroimaging studies are required to define the etiology of a primary IVH. CT does not provide significant information about the cerebral vasculature, and it has limited ability to identify malignancies. In the absence of an obvious precipitant such as trauma or coagulopathy, most patients with primary IVH should undergo further neuroimaging, typically to include magnetic resonance imaging and magnetic resonance angiography",
"    <span class=\"nowrap\">",
"     (MRI/MRA).",
"    </span>",
"   </p>",
"   <p>",
"    If",
"    the",
"    <span class=\"nowrap\">",
"     MRI/MRA",
"    </span>",
"    is unrevealing, conventional angiography should follow. In a prospective observational study of patients with IVH who underwent catheter angiography, vascular lesions were found in 11 of 17 (65 percent), including 10 patients with arteriovenous malformations, and one with aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/13\">",
"     13",
"    </a>",
"    ]. A retrospective review of published case series similarly estimated the yield of angiography at 56 percent, additionally identifying cases of Moyamoya and dural arteriovenous fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2\">",
"     2",
"    </a>",
"    ]. If the cause of the IVH remains undetermined, it is reasonable in some cases to consider repeat contrast MRI and possibly catheter angiography one to two months following the initial studies after reabsorption of blood products has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that are important to include are blood clotting studies (PT, PTT, and platelet count). A toxicology screen should also be considered.",
"   </p>",
"   <p>",
"    Because electrolyte imbalances can complicate IVH, these should be measured at baseline and followed regularly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of IVH focuses on cessation of bleeding, relieving hydrocephalus, and controlling intracranial pressure (ICP).",
"   </p>",
"   <p>",
"    Specific therapy aimed at treating the underlying cause should be undertaken (aneurysm or arteriovenous malformation obliteration). Coagulopathies should be corrected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have a moderate to severe IVH (impaired alertness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    GS &gt;8) should be followed in an intensive care setting. Medical complications are common (eg, pneumonia, deep venous thrombosis, gastrointestinal bleeding, cardiovascular instability, supraventricular tachycardia, hypo- and hypernatremia) requiring appropriate monitoring and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. The head of the bed should be placed at 30 degrees or greater to decrease ICP and reduce the risk of aspiration. Euvolemia should be maintained using isotonic crystalloid solutions, and any elevations in body temperature should be treated aggressively.",
"   </p>",
"   <p>",
"    For prevention of deep venous thrombosis, mechanical thromboprophylaxis using intermittent pneumatic compression stockings is recommended until a bleeding source has been identified and secured. At that time, antithrombotic therapy can be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because seizures are an infrequent complication of IVH, prophylactic antiepileptic drugs are not generally used; but should be initiated immediately should seizures occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Blood pressure management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimum blood pressure management in patients with IVH remains undefined. Aggressive blood pressure lowering may minimize the risk of further hemorrhage, but must be weighed against the risk of decreased cerebral perfusion in patients with increased ICP. One small pilot trial in 48 patients with IVH found a significantly decreased risk of hemorrhage enlargement in patients who achieved a prespecified goal of lowering mean arterial pressure by 30 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It seems reasonable to gradually lower elevated blood pressure in patients with normal ICP. Intravenous antihypertensives such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    are typically used, although other agents are acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/44\">",
"     44",
"    </a>",
"    ]. In the absence of better data specific to IVH, the guidelines outlined for blood pressure management in the setting of ICH seem reasonable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     External ventricular drain",
"    </span>",
"    &nbsp;&mdash;&nbsp;An external ventricular drain (EVD) is a small catheter inserted through the skull usually into the lateral ventricle, which is typically connected to a closed collecting device to allow for drainage of cerebrospinal fluid (",
"    <a class=\"graphic graphic_figure graphicRef56391 \" href=\"UTD.htm?27/61/28625\">",
"     figure 1",
"    </a>",
"    ). The EVD can also be connected to a transducer that records ICP.",
"   </p>",
"   <p>",
"    An EVD is indicated for patients with IVH with hydrocephalus and neurologic decline. Rarely, bilateral EVDs may be needed if hemorrhage obstructs the foramen of Monro [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major complications associated with EVD are catheter occlusion due to clotted blood at the intraventricular orifice and infection. The former may be relieved by irrigation or catheter replacement. Symptoms suggestive of infection should prompt cerebrospinal fluid analysis for cell count and culture along with antibiotic therapy as appropriate. Staphylococci are the most common pathogens. Higher rates of bacterial",
"    <span class=\"nowrap\">",
"     ventriculitis/meningitis",
"    </span>",
"    occur with longer duration of EVD placement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/46\">",
"     46",
"    </a>",
"    ]. In one study, those with infection had a mean duration of EVD of 17 days compared to 10 days in those who did not develop infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/46\">",
"     46",
"    </a>",
"    ]. Prophylactic catheter change does not clearly improve the risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=see_link\">",
"     \"Infections of central nervous system shunts and other devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intraventricular thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications associated with EVD provide a rationale for the use of intraventricular thrombolysis (IVT). Theoretically, instillation of thrombolytic agents into the ventricles can speed clot resolution, avoiding problems with catheter occlusion and shortening the duration of EVD use. It is also possible, although unproven, that more rapid resolution of IVH may decrease the long-term incidence of communicating hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/4\">",
"     4",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H18\">",
"     'Prognosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A number of small case series have provided support for IVT, showing increased clot resolution and decreased mortality compared with nonrandomized or historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/3,35,47-55\">",
"     3,35,47-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case-control study reported that after multivariate analysis, IVT did not affect long-term outcomes although it did hasten clot lysis and reduced repeat EVD placement and long-term shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/56\">",
"     56",
"    </a>",
"    ]. In a randomized study of 12 patients with IVH, intraventricular injections at 12 hour intervals were associated with significantly greater clot resolution than injection with normal saline [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/57\">",
"     57",
"    </a>",
"    ]. This trial was stopped after urokinase was no longer available. The Intraventricular Hemorrhage Thrombolysis Trial, a multicenter randomized controlled study, enrolled 48 patients and compared 3 mg rt-PA to normal saline injected through an EVD every twelve hours until clot reduction or a clinical endpoint occurred (median duration of dosing was 7.5 days for rtPA and 12 days for placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/58\">",
"     58",
"    </a>",
"    ]. The rate of clot resolution was faster for rtPA than placebo (18 versus 8 percent per day). Rates of death and ventriculitis were lower than expected and did not differ significantly between treatment groups. Symptomatic bleeding complications were more frequent in the rtPA group (23 versus 5 percent), but this did not reach statistical significance. Observational data suggest that lower doses of rt-PA (3",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may be safer and equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger randomized studies are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/60\">",
"     60",
"    </a>",
"    ]. As an example, Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR-III) is comparing treatment with 1 mg rt-PA or placebo injected through an EVD every eight hours until clot reduction or a clinical endpoint occurs, or 12 doses have been given. Preliminary safety data based on the first 36 patients enrolled showed a mortality rate of 8 percent, symptomatic rebleeding rate of 8 percent, and no bacterial ventriculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bleeding complications are a concern with IVT; recurrent IVH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICH expansion is reported in 8 to 20 percent of patients after IVT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/15,36,53,54,58,62\">",
"     15,36,53,54,58,62",
"    </a>",
"    ]. Typically, patients with known aneurysm or vascular malformation were excluded from early studies of IVT. However, IVT has been used without complication in a few reported cases after the vascular malformation or aneurysm was surgically treated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/15,63-65\">",
"     15,63-65",
"    </a>",
"    ], and even before surgery, in few patients with these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/16,66\">",
"     16,66",
"    </a>",
"    ]. Systemic bleeding complications are unlikely to be significantly increased with IVT; in CLEAR IVH, systemic coagulation parameters were similar after administration of rtPA and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also possible that the risk of bacterial",
"    <span class=\"nowrap\">",
"     meningitis/ventriculitis",
"    </span>",
"    may be increased with IVT therapy, but this has not been demonstrated so far [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/36,53,58\">",
"     36,53,58",
"    </a>",
"    ]. IVT has not been associated with systemic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that the use of IVT in patients with IVH be restricted to patients who do not have an unsecured vascular malformation or aneurysm, a large intraparenchymal hemorrhage, or a coagulopathy and also to experienced centers that have an established IVT protocol. An example of such a protocol is provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef54351 \" href=\"UTD.htm?40/56/41867\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other reported approaches to prevention and treatment of hydrocephalus in this setting are investigational:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of a neuroendovascular approach to extract intraventricular blood appears promising in a handful of case studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endoscopic third ventriculostomy has also been used in a number of reported cases to treat acute hydrocephalus related to IVH [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other centers have reported mixed results with surgical removal of hemorrhage via an open craniotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/73,74\">",
"       73,74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported in-hospital mortality of IVH varies from 20 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1,2,4,9-11,30,53\">",
"     1,2,4,9-11,30,53",
"    </a>",
"    ]. Secondary IVH carries a higher risk of death than primary IVH [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/14,30,68\">",
"     14,30,68",
"    </a>",
"    ]. Advanced age, underlying coagulopathy, Glasgow coma scale score of 8 or less, hydrocephalus at presentation are also associated with a higher risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2,11,30,37,68\">",
"     2,11,30,37,68",
"    </a>",
"    ]. While many studies have found that the extent of IVH (high Graeb score) correlates with prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/2,11,37\">",
"     2,11,37",
"    </a>",
"    ], others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/9,10,14\">",
"     9,10,14",
"    </a>",
"    ]. The results of one study found that the volume of blood in the third ventricle was a strong and independent predictor of poor outcomes, while the volume of blood in the lateral ventricles, fourth ventricle, or entire ventricular system did not correlate significantly with prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/75\">",
"     75",
"    </a>",
"    ]. The authors speculated that blood in the third ventricle may affect critical contiguous structures in the midbrain.",
"   </p>",
"   <p>",
"    Other long-term complications of IVH include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurocognitive sequelae. Patients with significant IVH are often confused, agitated and disoriented [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1\">",
"       1",
"      </a>",
"      ]. These symptoms are often slow to recover and a significant proportion (about half of survivors) are left with disabling cognitive deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/1,10,15\">",
"       1,10,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Noncommunicating hydrocephalus. IVH along with a secondary",
"      <span class=\"nowrap\">",
"       inflammatory/fibrotic",
"      </span>",
"      response may lead to impaired absorption of cerebrospinal fluid at the arachnoid granulations. This may be manifest by a more subacute decline in cognition, gait, and urinary continence that can occur weeks or later after the initial IVH, or as a failure to wean off EVD. Such patients may require permanent ventriculoperitoneal shunt [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/36\">",
"       36",
"      </a>",
"      ]. Approximately 30 to 50 percent of patients with IVH require a shunt placement [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/15,49,53,64,76-79\">",
"       15,49,53,64,76-79",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=see_link\">",
"       \"Normal pressure hydrocephalus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late recurrence of intracerebral or intraventricular hemorrhage. Recurrent hemorrhage is uncommonly reported after IVH. In one series, 2 of 14 survivors had a subsequent intracerebral hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/11\">",
"       11",
"      </a>",
"      ], while in another series there was no recurrent bleeding in a group of 13 patients after 67 months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/10\">",
"       10",
"      </a>",
"      ]. The risk of this complication is likely highest in those with an unrecognized",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unsecured vascular lesion (eg, Moyamoya) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6009/abstract/26,80\">",
"       26,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraventricular hemorrhage (IVH) can complicate intracerebral hemorrhage or subarachnoid hemorrhage (SAH) (secondary IVH). Less commonly, IVH occurs in isolation (primary IVH).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most commonly identified cause of primary IVH is a vascular malformation. Up to half of patients with primary IVH do not have a cause (other than hypertension) identified. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary IVH usually presents with sudden headache, nausea and vomiting, and impaired alertness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a clinical presentation of IVH should undergo immediate noncontrast head CT. The primary purpose is to exclude SAH and to identify the IVH and evaluate its severity and potential for obstructive hydrocephalus. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals with primary IVH should have magnetic resonance imaging (MRI) with MR angiography",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      conventional angiography to identify the underlying etiology, particularly a vascular malformation or aneurysm that may require surgical intervention. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Other neuroimaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because acute obstructive hydrocephalus often complicates IVH that involves the third and fourth ventricles, such patients should be closely monitored. When neurologic deterioration occurs, emergent CT scan should be done to exclude the development of obstructive hydrocephalus or recurrent hemorrhage. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend external ventricular drainage for neurologic deterioration that occurs with ventricular enlargement. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'External ventricular drain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of intraventricular thrombolysis holds promise for improved outcomes in patients with IVH and obstructive hydrocephalus, but definitive recommendations await the results of further clinical trials. The use of intraventricular thrombolysis can be considered in experienced centers that have established protocols. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Intraventricular thrombolysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18042404\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. James Pacelli, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/1\">",
"      Darby DG, Donnan GA, Saling MA, et al. Primary intraventricular hemorrhage: clinical and neuropsychological findings in a prospective stroke series. Neurology 1988; 38:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/2\">",
"      Flint AC, Roebken A, Singh V. Primary intraventricular hemorrhage: yield of diagnostic angiography and clinical outcome. Neurocrit Care 2008; 8:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/3\">",
"      Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke 2009; 40:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/4\">",
"      Nyquist P, Hanley DF. The use of intraventricular thrombolytics in intraventricular hemorrhage. J Neurol Sci 2007; 261:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/5\">",
"      Biffi A, Battey TW, Ayres AM, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology 2011; 77:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/6\">",
"      LeRoux PD, Haglund MM, Newell DW, et al. Intraventricular hemorrhage in blunt head trauma: an analysis of 43 cases. Neurosurgery 1992; 31:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/7\">",
"      Inamasu J, Hori S, Aikawa N. Traumatic intraventricular hemorrhage causing talk and deteriorate syndrome. Am J Emerg Med 2001; 19:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/8\">",
"      Atzema C, Mower WR, Hoffman JR, et al. Prevalence and prognosis of traumatic intraventricular hemorrhage in patients with blunt head trauma. J Trauma 2006; 60:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/9\">",
"      Angelopoulos M, Gupta SR, Azat Kia B. Primary intraventricular hemorrhage in adults: clinical features, risk factors, and outcome. Surg Neurol 1995; 44:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/10\">",
"      Mart&iacute;-F&agrave;bregas J, Piles S, Guardia E, Mart&iacute;-Vilalta JL. Spontaneous primary intraventricular hemorrhage: clinical data, etiology and outcome. J Neurol 1999; 246:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/11\">",
"      Passero S, Ulivelli M, Reale F. Primary intraventricular haemorrhage in adults. Acta Neurol Scand 2002; 105:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/12\">",
"      Findlay, JM. Intraventricular hemorrhage. Neurosurgery Quarterly 2000; 10:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/13\">",
"      Zhu XL, Chan MS, Poon WS. Spontaneous intracranial hemorrhage: which patients need diagnostic cerebral angiography? A prospective study of 206 cases and review of the literature. Stroke 1997; 28:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/14\">",
"      Roos YB, Hasan D, Vermeulen M. Outcome in patients with large intraventricular haemorrhages: a volumetric study. J Neurol Neurosurg Psychiatry 1995; 58:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/15\">",
"      Goh KY, Poon WS. Recombinant tissue plasminogen activator for the treatment of spontaneous adult intraventricular hemorrhage. Surg Neurol 1998; 50:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/16\">",
"      Kumar K, Demeria DD, Verma A. Recombinant tissue plasminogen activator in the treatment of intraventricular hemorrhage secondary to periventricular arteriovenous malformation before surgery: case report. Neurosurgery 2003; 52:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/17\">",
"      Irie F, Fujimoto S, Uda K, et al. Primary intraventricular hemorrhage from dural arteriovenous fistula. J Neurol Sci 2003; 215:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/18\">",
"      Gerard E, Frontera JA, Wright CB. Vasospasm and cerebral infarction following isolated intraventricular hemorrhage. Neurocrit Care 2007; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/19\">",
"      Okamura A, Goto S, Sato K, Ushio Y. Central neurocytoma with hemorrhagic onset. Surg Neurol 1995; 43:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/20\">",
"      Lee EJ, Choi KH, Kang SW, Lee IW. Intraventricular hemorrhage caused by lateral ventricular meningioma: a case report. Korean J Radiol 2001; 2:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/21\">",
"      Vates GE, Arthur KA, Ojemann SG, et al. A neurocytoma and an associated lenticulostriate artery aneurysm presenting with intraventricular hemorrhage: case report. Neurosurgery 2001; 49:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/22\">",
"      Lindboe CF, Stolt-Nielsen A, Dale LG. Hemorrhage in a highly vascularized subependymoma of the septum pellucidum: case report. Neurosurgery 1992; 31:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/23\">",
"      Smets K, Salgado R, Simons PJ, et al. Central neurocytoma presenting with intraventricular hemorrhage: case report and review of literature. Acta Neurol Belg 2005; 105:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/24\">",
"      Zuccaro G, Sosa F, Cuccia V, et al. Lateral ventricle tumors in children: a series of 54 cases. Childs Nerv Syst 1999; 15:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/25\">",
"      Akamatsu Y, Utsunomiya A, Suzuki S, et al. Subependymoma in the lateral ventricle manifesting as intraventricular hemorrhage. Neurol Med Chir (Tokyo) 2010; 50:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/26\">",
"      Hamada J, Hashimoto N, Tsukahara T. Moyamoya disease with repeated intraventricular hemorrhage due to aneurysm rupture. Report of two cases. J Neurosurg 1994; 80:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/27\">",
"      Khan M, Novakovic RL, Rosengart AJ. Intraventricular hemorrhage disclosing neurofibromatosis 1 and moyamoya phenomena. Arch Neurol 2006; 63:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/28\">",
"      Jabbour R, Taher A, Shamseddine A, Atweh SF. Moyamoya syndrome with intraventricular hemorrhage in an adult with factor V Leiden mutation. Arch Neurol 2005; 62:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/29\">",
"      Ionita CC, Ferrara J, McDonagh DL, et al. Systemic hemostasis with recombinant-activated factor VII followed by local thrombolysis with recombinant tissue plasminogen activator in intraventricular hemorrhage. Neurocrit Care 2005; 3:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/30\">",
"      Kiymaz N, Demir O, Cirak B. Is external ventricular drainage useful in primary intraventricular hemorrhages? Adv Ther 2005; 22:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/31\">",
"      Challa VR, Richards F 2nd, Davis CH Jr. Intraventricular hemorrhage from pituitary apoplexy. Surg Neurol 1981; 16:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/32\">",
"      Kishimoto M, Arakawa KC. A patient with wegener granulomatosis and intraventricular hemorrhage. J Clin Rheumatol 2003; 9:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/33\">",
"      Imanse J, Vanneste J. Intraventricular hemorrhage following amphetamine abuse. Neurology 1990; 40:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/34\">",
"      Ziai WC, Triantaphyllopoulou A, Razumovsky AY, Hanley DF. Treatment of sympathomimetic induced intraventricular hemorrhage with intraventricular urokinase. J Stroke Cerebrovasc Dis 2003; 12:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/35\">",
"      Rohde V, Schaller C, Hassler WE. Intraventricular recombinant tissue plasminogen activator for lysis of intraventricular haemorrhage. J Neurol Neurosurg Psychiatry 1995; 58:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/36\">",
"      Nyquist P, LeDroux S, Geocadin R. Thrombolytics in intraventricular hemorrhage. Curr Neurol Neurosci Rep 2007; 7:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/37\">",
"      Nishikawa T, Ueba T, Kajiwara M, et al. A priority treatment of the intraventricular hemorrhage (IVH) should be performed in the patients suffering intracerebral hemorrhage with large IVH. Clin Neurol Neurosurg 2009; 111:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/38\">",
"      Dull C, Torbey MT. Cerebral vasospasm associated with intraventricular hemorrhage. Neurocrit Care 2005; 3:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/39\">",
"      Maeda K, Kurita H, Nakamura T, et al. Occurrence of severe vasospasm following intraventricular hemorrhage from an arteriovenous malformation. Report of two cases. J Neurosurg 1997; 87:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/40\">",
"      Graeb DA, Robertson WD, Lapointe JS, et al. Computed tomographic diagnosis of intraventricular hemorrhage. Etiology and prognosis. Radiology 1982; 143:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/41\">",
"      Hallevi H, Dar NS, Barreto AD, et al. The IVH score: a novel tool for estimating intraventricular hemorrhage volume: clinical and research implications. Crit Care Med 2009; 37:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/42\">",
"      Kiphuth IC, Huttner HB, Struffert T, et al. Sonographic monitoring of ventricle enlargement in posthemorrhagic hydrocephalus. Neurology 2011; 76:858.",
"     </a>",
"    </li>",
"    <li>",
"     Daniel Hanley, 2005, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/44\">",
"      Narotam PK, Puri V, Roberts JM, et al. Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. J Neurosurg 2008; 109:1065.",
"     </a>",
"    </li>",
"    <li>",
"     Findlay JM. Intraventricular Hemorrhage. In: Pathophysiology Diagnosis and Managment, 4th ed, Mohr JPC D, Grotta J, Weir B, Wolf P (Eds).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/46\">",
"      Pfausler B, Beer R, Engelhardt K, et al. Cell index--a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)-related ventriculitis in patients with intraventricular hemorrhage? Acta Neurochir (Wien) 2004; 146:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/47\">",
"      Findlay JM, Grace MG, Weir BK. Treatment of intraventricular hemorrhage with tissue plasminogen activator. Neurosurgery 1993; 32:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/48\">",
"      Naff NJ, Carhuapoma JR, Williams MA, et al. Treatment of intraventricular hemorrhage with urokinase : effects on 30-Day survival. Stroke 2000; 31:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/49\">",
"      Coplin WM, Vinas FC, Agris JM, et al. A cohort study of the safety and feasibility of intraventricular urokinase for nonaneurysmal spontaneous intraventricular hemorrhage. Stroke 1998; 29:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/50\">",
"      Rainov NG, Burkert WL. Urokinase infusion for severe intraventricular haemorrhage. Acta Neurochir (Wien) 1995; 134:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/51\">",
"      Nieuwkamp DJ, de Gans K, Rinkel GJ, Algra A. Treatment and outcome of severe intraventricular extension in patients with subarachnoid or intracerebral hemorrhage: a systematic review of the literature. J Neurol 2000; 247:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/52\">",
"      Vereecken KK, Van Havenbergh T, De Beuckelaar W, et al. Treatment of intraventricular hemorrhage with intraventricular administration of recombinant tissue plasminogen activator A clinical study of 18 cases. Clin Neurol Neurosurg 2006; 108:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/53\">",
"      Fountas KN, Kapsalaki EZ, Parish DC, et al. Intraventricular administration of rt-PA in patients with intraventricular hemorrhage. South Med J 2005; 98:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/54\">",
"      Staykov D, Huttner HB, Struffert T, et al. Intraventricular fibrinolysis and lumbar drainage for ventricular hemorrhage. Stroke 2009; 40:3275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/55\">",
"      Gaberel T, Magheru C, Parienti JJ, et al. Intraventricular fibrinolysis versus external ventricular drainage alone in intraventricular hemorrhage: a meta-analysis. Stroke 2011; 42:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/56\">",
"      Huttner HB, Tognoni E, Bardutzky J, et al. Influence of intraventricular fibrinolytic therapy with rt-PA on the long-term outcome of treated patients with spontaneous basal ganglia hemorrhage: a case-control study. Eur J Neurol 2008; 15:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/57\">",
"      Naff NJ, Hanley DF, Keyl PM, et al. Intraventricular thrombolysis speeds blood clot resolution: results of a pilot, prospective, randomized, double-blind, controlled trial. Neurosurgery 2004; 54:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/58\">",
"      Naff N, Williams MA, Keyl PM, et al. Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial. Stroke 2011; 42:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/59\">",
"      Staykov D, Wagner I, Volbers B, et al. Dose effect of intraventricular fibrinolysis in ventricular hemorrhage. Stroke 2011; 42:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/60\">",
"      Mattle HP, Raabe A. CLEAR intraventricular hemorrhage: more than a glimmer of hope. Stroke 2011; 42:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/61\">",
"      Morgan T, Awad I, Keyl P, et al. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl 2008; 105:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/62\">",
"      Schwarz S, Schwab S, Steiner HH, Hacke W. Secondary hemorrhage after intraventricular fibrinolysis: a cautionary note: a report of two cases. Neurosurgery 1998; 42:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/63\">",
"      Pollock GA, Shaibani A, Awad I, et al. Intraventricular Hemorrhage Secondary to Intranidal Aneurysm Rupture: Successful management by AVM embolization followed by intraventricular tPA: Case Report. Neurosurgery 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/64\">",
"      Varelas PN, Rickert KL, Cusick J, et al. Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator. Neurosurgery 2005; 56:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/65\">",
"      Findlay JM, Jacka MJ. Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage. Neurosurgery 2004; 55:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/66\">",
"      Mayfrank L, Rohde V, Gilsbach JM. Fibrinolytic treatment of intraventricular haemorrhage preceding surgical repair of ruptured aneurysms and arteriovenous malformations. Br J Neurosurg 1999; 13:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/67\">",
"      Herrick DB, Ziai WC, Thompson CB, et al. Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group. Stroke 2011; 42:3631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/68\">",
"      Engelhard HH, Andrews CO, Slavin KV, Charbel FT. Current management of intraventricular hemorrhage. Surg Neurol 2003; 60:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/69\">",
"      Andrews CO, Engelhard HH. Fibrinolytic therapy in intraventricular hemorrhage. Ann Pharmacother 2001; 35:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/70\">",
"      Longatti P, Fiorindi A, Di Paola F, et al. Coiling and neuroendoscopy: a new perspective in the treatment of intraventricular haemorrhages due to bleeding aneurysms. J Neurol Neurosurg Psychiatry 2006; 77:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/71\">",
"      Longatti PL, Martinuzzi A, Fiorindi A, et al. Neuroendoscopic management of intraventricular hemorrhage. Stroke 2004; 35:e35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/72\">",
"      Oertel JM, Mondorf Y, Baldauf J, et al. Endoscopic third ventriculostomy for obstructive hydrocephalus due to intracranial hemorrhage with intraventricular extension. J Neurosurg 2009; 111:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/73\">",
"      Onoda K, Kurozumi K, Tsuchimoto S, Satoh T. Experience with the high occipital transcortical approach in the treatment of intraventricular hemorrhage. Report of two cases. J Neurosurg 2001; 94:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/74\">",
"      Lagares A, Putman CM, Ogilvy CS. Posterior fossa decompression and clot evacuation for fourth ventricle hemorrhage after aneurysmal rupture: case report. Neurosurgery 2001; 49:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/75\">",
"      Staykov D, Volbers B, Wagner I, et al. Prognostic significance of third ventricle blood volume in intracerebral haemorrhage with severe ventricular involvement. J Neurol Neurosurg Psychiatry 2011; 82:1260.",
"     </a>",
"    </li>",
"    <li>",
"     Findlay JM. Intraventricular Hemorrhage. In: Stroke: Pathophysiology Diagnosis and Management, 4th ed, Mohr JP, Choi DW, Grotta JC, Weir B, Wolf PA (Eds), Churchill Livingstone 2004. p.1231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/77\">",
"      Vale FL, Bradley EL, Fisher WS 3rd. The relationship of subarachnoid hemorrhage and the need for postoperative shunting. J Neurosurg 1997; 86:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/78\">",
"      Graff-Radford NR, Torner J, Adams HP Jr, Kassell NF. Factors associated with hydrocephalus after subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. Arch Neurol 1989; 46:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/79\">",
"      Miller C, Tsivgoulis G, Nakaji P. Predictors of ventriculoperitoneal shunting after spontaneous intraparenchymal hemorrhage. Neurocrit Care 2008; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6009/abstract/80\">",
"      Kobayashi E, Saeki N, Oishi H, et al. Long-term natural history of hemorrhagic moyamoya disease in 42 patients. J Neurosurg 2000; 93:976.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1116 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6009=[""].join("\n");
var outline_f5_55_6009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY OF PRIMARY IVH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other neuroimaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Blood pressure management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      External ventricular drain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intraventricular thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18042404\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1116|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/61/28625\" title=\"figure 1\">",
"      External ventricular device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1116|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/1/30747\" title=\"table 2\">",
"      Etiologies of thunderclap headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/56/41867\" title=\"table 3\">",
"      Chicago protocol for treatment of IVH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19112?source=related_link\">",
"      Intracranial epidural hematoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/50/38696?source=related_link\">",
"      Nonaneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=related_link\">",
"      Normal pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43767?source=related_link\">",
"      Subdural hematoma in adults: Prognosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_55_6010="Diagnosis and differential diagnosis of rheumatoid arthritis";
var content_f5_55_6010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and differential diagnosis of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6010/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6010/contributors\">",
"     PJW Venables, MA, MB BChir, MD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6010/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6010/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6010/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/55/6010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/55/6010/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/55/6010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a symmetric, inflammatory, peripheral polyarthritis of unknown etiology. It typically leads to deformity through the stretching of tendons and ligaments and destruction of joints through the erosion of cartilage and bone. If it is untreated or unresponsive to therapy, inflammation and joint destruction lead to loss of physical function, inability to carry out daily tasks of living, and maintenance of employment.",
"   </p>",
"   <p>",
"    Early recognition and treatment with disease-modifying antirheumatic drugs is important in achieving control of disease and prevention of joint injury and disability. However, in patients with early disease, the joint manifestations are often difficult to distinguish from other forms of inflammatory polyarthritis. The more distinctive signs of RA, such as joint erosions, rheumatoid nodules, and other extraarticular manifestations, are seen primarily in patients with longstanding, poorly-controlled disease but are frequently absent on initial presentation.",
"   </p>",
"   <p>",
"    This topic will review the approach to the diagnosis and differential diagnosis of RA. The clinical features of this disorder, its extraarticular manifestations, and laboratory markers that are clinically useful in the diagnosis of RA are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8594869\">",
"    <span class=\"h1\">",
"     EVALUATION FOR SUSPECTED RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA should be suspected in the adult patient who presents with inflammatory polyarthritis. The initial evaluation of such patients requires a careful history and physical examination, along with selected laboratory testing to identify features that are characteristic of RA or that suggest an alternative diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We focus especially on the following for the purposes of diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We perform a thorough medical history, with particular attention to joint pain, reported swelling, and the presence, location (peripheral joints rather than low back), and duration (at least 30 minutes) of morning stiffness. The absence of other conditions or symptoms suggesting an alternative diagnosis, such as psoriasis, inflammatory bowel disease, or a systemic rheumatic disease such as systemic lupus erythematosus (SLE), helps to exclude other disorders.",
"      <br/>",
"      <br/>",
"      Symptoms of arthritis that have been present for a short time (for example, less than six weeks) may well be due to an acute viral polyarthritis rather than to RA. The longer symptoms persist, the more likely the diagnosis of RA becomes. Thus, in patients presenting very early, close observation with frequent follow-up appointments is required, with repeated serologic analysis for anti-cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor, and acute-phase reactants. In a minority of patients, several such visits are required before the differential diagnosis between RA and viral arthritis becomes established. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Typical \"classic\" RA'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A complete physical examination is indicated to assess for synovitis, including the presence and distribution of swollen or tender joints and limited joint motion; extraarticular disease manifestations, such as rheumatoid nodules; and signs of diseases, such as systemic lupus erythematosus or psoriasis, included in the differential diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Physical findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link\">",
"       \"Rheumatoid nodules\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We perform the following laboratory tests, which support the diagnosis if positive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies &mdash; We perform both RF and anti-CCP antibody testing when initially evaluating a patient with suspected RA. The results of both tests are informative, since a positive result for either test increases overall diagnostic sensitivity, while the specificity is increased when both tests are positive. Despite this, both tests are negative on presentation in up to 50 percent of patients and remain negative during follow-up in 20 percent of patients with RA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Rheumatoid factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) levels &mdash;Both the ESR and CRP are typically elevated in RA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Erythrocyte sedimentation rate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'C-reactive protein'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We perform the following testing in all patients, which may be helpful in the differential diagnosis of RA and as baseline testing for monitoring of disease activity or progression and medication safety:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antinuclear antibody (ANA) testing &mdash; A negative ANA helps exclude SLE and other systemic rheumatic diseases; the ANA may be positive in up to one-third of patients with RA. In patients with a positive ANA, anti-double stranded DNA and anti-Smith antibody testing should also be performed; these antibodies have high specificity for SLE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"       \"Measurement and clinical significance of antinuclear antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete blood count (CBC) with differential and platelet count, tests of liver and kidney function, serum uric acid, and a urinalysis &mdash; The CBC is often abnormal in RA, with anemia and thrombocytosis consistent with chronic inflammation. Liver and kidney testing abnormalities indicate a disorder other than RA; if caused by comorbid conditions, they may affect therapeutic choices or drug dosing. Hyperuricemia may prompt additional efforts, including arthrocentesis and crystal search, to exclude gout; polyarticular gout can infrequently be mistaken for RA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H3#H3\">",
"       \"Hematologic manifestations of rheumatoid arthritis\", section on 'Anemia of chronic disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=see_link&amp;anchor=H17#H17\">",
"       \"Hematologic manifestations of rheumatoid arthritis\", section on 'Platelet abnormalities'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Radiographs of the hands, wrists, and feet &mdash; We obtain radiographs during the initial evaluation primarily as a baseline for monitoring disease progression. However, characteristic joint erosions may be observed in patients presenting with symptoms for the first time and, hence, aid in diagnosis. Additionally, in patients with other disorders, such as psoriatic arthritis, spondyloarthropathy, gout, or chondrocalcinosis, radiographic changes more characteristic of these conditions may point to an alternative diagnosis. (See",
"      <a class=\"local\" href=\"#H12499388\">",
"       '2010 ACR/EULAR criteria'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H1597644#H1597644\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We perform the following studies in selected patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serologic studies for infection &mdash; In patients with a very short history (for example, less than six weeks) particularly those who are seronegative for anti-CCP and rheumatoid factor, we perform serologic testing for human parvovirus B19, hepatitis B virus (HBV), and hepatitis C virus (HCV). In areas endemic for Lyme disease, we perform serologic studies for Borrelia as well. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute viral polyarthritis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"       \"Specific viruses that cause arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnosis of Lyme disease\", section on 'Indications for serologic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Synovial fluid analysis &mdash; We perform arthrocentesis and synovial fluid analysis for the diagnosis or exclusion of gout, pseudogout, or an infectious arthritis if a joint effusion is present and if there is uncertainty regarding the diagnosis, particularly in the setting a monoarthritis, oligoarthritis, or asymmetric joint inflammation. Synovial fluid testing should include a cell count and differential, crystal search, as well as Gram stain and culture. Synovial fluid analysis should also be obtained to exclude infection or crystalline arthropathy in patients who undergo glucocorticoid injections for symptomatic relief. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H1597589#H1597589\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Laboratory findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MRI and ultrasound &mdash; Magnetic resonance imaging (MRI) studies and ultrasonography do not have an established role in the routine evaluation of patients with polyarthritis. However, MRI and ultrasound are more sensitive than radiography at detecting changes resulting from synovitis and may be helpful in establishing the presence of synovitis in patients with normal radiographs and uncertainty regarding either the diagnosis or the presence of inflammatory changes, such as patients with obesity or subtle findings on examination. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H1597644#H1597644\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8594876\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205867198\">",
"    <span class=\"h2\">",
"     Our diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RA can be made when the following clinical features are all present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory arthritis involving three or more joints (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features of rheumatoid arthritis\", section on 'Physical findings'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Positive rheumatoid factor (RF)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-citrullinated",
"      <span class=\"nowrap\">",
"       peptide/protein",
"      </span>",
"      antibody (such as anti-CCP) testing (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elevated levels of C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Erythrocyte sedimentation rate'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diseases with similar clinical features have been excluded, particularly psoriatic arthritis, acute viral polyarthritis, polyarticular gout or calcium pyrophosphate deposition disease, and systemic lupus erythematosus. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The duration of symptoms is more than six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria are consistent with the 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    classification criteria for RA. (See",
"    <a class=\"local\" href=\"#H12499388\">",
"     '2010 ACR/EULAR criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis of RA may also be made in some patients who do not meet all of our criteria. (See",
"    <a class=\"local\" href=\"#H10758726\">",
"     'Patients not meeting above criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205867160\">",
"    <span class=\"h3\">",
"     Inflammatory arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritis is typically present in the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints of the hands. The wrists are also commonly involved, as are the metatarsophalangeal (MTP) joints in the feet, but any upper or lower extremity joint may be affected. Symmetric polyarthritis, particularly of the MCP, MTP,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PIP joints, strongly suggests RA. Although distal interphalangeal (DIP) joint disease can occur in patients with RA, DIP involvement strongly suggests a diagnosis of osteoarthritis or psoriatic arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of rheumatoid arthritis\", section on 'Physical findings'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H24\">",
"     'Osteoarthritis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Psoriatic arthritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205867167\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid factors (RF) occur in 70 to 80 percent of patients with RA. Their diagnostic utility is limited by their relatively poor specificity since they are found in 5 to 10 percent of healthy individuals, in 20 to 30 percent of people with SLE, in virtually all patients with mixed cryoglobulinemia (usually caused by hepatitis C virus infections), and in those with many other inflammatory conditions. Higher titers of RF (at least three times the upper limit of normal) have somewhat greater specificity for RA. The prevalence of RF positivity in healthy individuals rises with age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=see_link\">",
"     \"Origin and utility of measurement of rheumatoid factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Rheumatoid factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibodies to citrullinated",
"    <span class=\"nowrap\">",
"     peptides/proteins",
"    </span>",
"    are usually measured by enzyme linked immunosorbent assays using cyclic citrullinated peptides (CCP) as antigen. Anti-CCP antibodies have a similar sensitivity to RF for RA but have a much higher specificity (95 to 98 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The specificity is greater in patients with higher titers of anti-CCP antibodies (at least three times the upper limit of normal). Another test, anti-mutated citrullinated vimentin, gives similar results to anti-CCP and is used as an alternative in some laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205867174\">",
"    <span class=\"h3\">",
"     Acute phase reactants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations of the ESR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CRP level are consistent with the presence of an inflammatory state, such as RA. Normal acute phase reactants may occur in untreated patients with RA, but such findings are very infrequent. The degree of elevation of these acute phase reactants varies with the severity of inflammation. As an example, an ESR of 50 to 80 is not uncommon in patients with severely active RA. By comparison, an ESR of 20 to 30 can be observed with only a few mildly to moderately active joints. Although increased levels of acute phase reactants are not specific for RA, they are often useful for distinguishing inflammatory conditions from noninflammatory disorders that present with musculoskeletal symptoms (eg, osteoarthritis or fibromyalgia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Erythrocyte sedimentation rate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'C-reactive protein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10758726\">",
"    <span class=\"h2\">",
"     Patients not meeting above criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RA may also be made in patients without all the criteria described in the previous section. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Seronegative RA",
"      </strong>",
"      &mdash; Patients who lack both rheumatoid factor and anti-CCP antibodies may be diagnosed with RA based upon findings otherwise characteristic of RA if appropriate exclusions have been met. Such patients with seronegative RA differ from anti-CCP-positive patients genetically and in their environmental risks, disease severity, and clinical responsiveness to some medications [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/6\">",
"       6",
"      </a>",
"      ]. Additional research is needed to better characterize this population.",
"     </li>",
"     <li>",
"      <strong>",
"       Recent onset RA &mdash;",
"      </strong>",
"      Patients with disease for less than six weeks may be diagnosed with RA based upon findings otherwise characteristic of RA, including anti-CCP antibodies, if testing for viral serologies is negative and if other appropriate exclusions have been met. (See",
"      <a class=\"local\" href=\"#H8594869\">",
"       'Evaluation for suspected RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute viral polyarthritis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Inactive RA",
"      </strong>",
"      &mdash; Patients without active arthritis or elevated acute phase reactants (eg, due to treatment of recent onset disease or with longstanding disease) may be diagnosed with RA based upon well-documented past findings characteristic of RA, especially in the presence of positive testing for RF and anti-CCP, or of typical bone erosions on radiography, and in the absence of an alternative more likely diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in the several categories above, and other patients who should be diagnosed with RA but do not meet our standard criteria, will generally have findings that are consistent with the 2010 American College of Rheumatology",
"    <span class=\"nowrap\">",
"     (ACR)/European",
"    </span>",
"    League Against Rheumatism (EULAR) classification criteria for RA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These criteria were developed for the classification of patients with RA for the purpose of epidemiologic studies and clinical trials, not primarily for clinical diagnosis. Nevertheless, the same features that are of value in classification tend to be useful for the purpose of diagnosis in clinical practice. Further study is required to establish their utility as diagnostic criteria in general practice. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Classification criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) classification criteria focus on features that would identify patients at an earlier stage of disease than would the previously used criteria that had been last revised in 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The 1987 ACR criteria were formulated to distinguish patients with established RA from patients with other defined rheumatic diseases; the 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    criteria for RA focused on identifying the factors, among patients newly presenting with undifferentiated inflammatory synovitis, which could allow for the identification of patients for whom the risk of symptom persistence or structural damage is sufficient to be considered for intervention with disease-modifying antirheumatic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12499388\">",
"    <span class=\"h2\">",
"     2010 ACR/EULAR criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    criteria (table of 2010",
"    <span class=\"nowrap\">",
"     ACR/EULAR",
"    </span>",
"    criteria shown at:",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp\">",
"     www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp",
"    </a>",
"    [accessed September 21, 2010]), classification as definite RA is based upon the presence of synovitis in at least one joint, the absence of an alternative diagnosis that better explains the synovitis, and the achievement of a total score of at least 6 (of a possible 10) from the individual scores in four domains. The highest score achieved in a given domain is used for this calculation. These domains and their values are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Number and site of involved joints",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      2 to 10 large joints (from among shoulders, elbows, hips, knees, and ankles) = 1 point",
"     </li>",
"     <li>",
"      1 to 3 small joints (from among the metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists) = 2 points",
"     </li>",
"     <li>",
"      4 to 10 small joints = 3 points",
"     </li>",
"     <li>",
"      Greater than 10 joints (including at least 1 small joint) = 5 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serological abnormality (rheumatoid factor or anti-citrullinated",
"      <span class=\"nowrap\">",
"       peptide/protein",
"      </span>",
"      antibody)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low positive (above the upper limit of normal, ULN) = 2 points",
"     </li>",
"     <li>",
"      High positive (greater than three times the ULN) = 3 points",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated acute phase response (erythrocyte sedimentation rate or C-reactive protein) above the ULN = 1 point",
"     </li>",
"     <li>",
"      Symptom duration at least six weeks = 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to those with the criteria above, which are best suited to patients with newly presenting disease, the following patients are classified as having RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with erosive disease typical of RA with a history compatible with prior fulfillment of the criteria above",
"     </li>",
"     <li>",
"      Patients with longstanding disease, including those whose disease is inactive (with or without treatment) who have previously fulfilled the criteria above based upon retrospectively available data",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165301\">",
"    <span class=\"h2\">",
"     1987 ACR criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to recognize that RA has been defined in virtually all clinical trials of drugs for RA initiated from 1987 through 2010 based upon the criteria developed and validated by the American College of Rheumatology (previously the American Rheumatism Association) in 1987 (",
"    <a class=\"graphic graphic_table graphicRef71659 \" href=\"UTD.htm?4/13/4316\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A patient was classified as having RA if at least four of these seven criteria were satisfied; four of the criteria must have been present for at least six weeks: morning stiffness, arthritis of three or more joint areas, arthritis of the hands, and symmetric arthritis. Rheumatoid factor was included as a criterion, but anti-CCP antibody testing was not available at that time. The other two criteria were rheumatoid nodules and radiographic erosive changes typical of RA, but these are generally not present in the early stages of disease.",
"   </p>",
"   <p>",
"    Thus, while these criteria were very good at separating inflammatory from noninflammatory arthritis, the major drawback of the 1987 criteria has been their insensitivity in identifying some patients with early disease who subsequently develop typical established RA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/10\">",
"     10",
"    </a>",
"    ]. On the other hand, the criteria did not require any exclusions, and patients could initially fulfill the diagnostic criteria but occasionally evolve into other diagnoses, particularly systemic lupus erythematosus (SLE), Sj&ouml;gren's syndrome, scleroderma, mixed connective tissue disease, psoriatic arthritis, and crystalline arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of conditions must be considered in the differential diagnosis of RA. Features of some disorders that are included in the differential diagnosis of RA are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef52176 \" href=\"UTD.htm?42/8/43149\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=see_link\">",
"     \"Evaluation of the adult with polyarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute viral polyarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of viral infections may cause an acute viral polyarthritis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral infections such as rubella [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/11\">",
"       11",
"      </a>",
"      ], parvovirus B19 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/12\">",
"       12",
"      </a>",
"      ], and HBV can cause an acute polyarthritis syndrome that may be mistaken for the inflammatory polyarthritis of RA. However, the syndrome is usually short-lived, lasting only from a few days to several weeks, and rarely beyond six weeks. HCV can cause a polyarthritis or oligoarthritis in a minority of patients but is more commonly associated with arthralgias.",
"      <br/>",
"      <br/>",
"      Serologic testing can help identify patients with HBV, HCV, or human parvovirus B19 in some individuals with early disease, but a viral etiology cannot always be excluded until after symptoms are present for at least six to eight weeks in the absence of diagnostic serologic testing for a specific virus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"       \"Specific viruses that cause arthritis\"",
"      </a>",
"      .) Unlike rheumatoid factor (which may occur in patients with a variety of infections, including HCV infection), anti-CCP antibodies are usually negative in patients with HCV infection who do not have RA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increasingly reported in travelers, alphaviruses are globally distributed mosquito-borne RNA viruses that cause epidemics of",
"      <span class=\"nowrap\">",
"       polyarthritis/arthralgia",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Among all of the viruses that can cause arthritis, the alphaviruses are unusual because nearly all symptomatic infections in adults result in joint symptoms. The incubation period lasts from several days to three weeks; infection is typically associated with triad of fever, arthritis, and rash [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/13\">",
"       13",
"      </a>",
"      ]. However, all aspects of the triad may not be present, thereby making the diagnosis difficult. One such alphavirus, Chikungunya, has become a global disease with increasing world travel and has caused large outbreaks in Italy, India, and Indian Ocean islands [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Alphavirus infections generally resolve over three to six months. The diagnosis of alphavirus infection can be made by appropriate serologic testing in travelers from endemic areas with persistent arthritic symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link&amp;anchor=H7#H7\">",
"       \"Specific viruses that cause arthritis\", section on 'Alphaviruses'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=see_link\">",
"       \"Chikungunya fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A large joint arthritis has been reported in association with human T lymphotropic virus type 1 (HTLV-I) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/17\">",
"       17",
"      </a>",
"      ]. These infections are sometimes associated with the presence of RFs (usually in low titer), antinuclear antibodies, and elevated acute phase reactants. HTLV-I infections can generally be distinguished from RA by the finding of specific antiviral antibodies and the typically self-limited nature of arthritis associated with HTLV-I.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Systemic rheumatic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early RA may be difficult to distinguish from the arthritis of systemic lupus erythematosus (SLE), Sj&ouml;gren's syndrome, dermatomyositis, or overlap syndromes, such as mixed connective tissue disease. In contrast with RA, these disorders are generally characterized by the presence of other systemic features, such as rashes, dry mouth and dry eyes, myositis, or nephritis, and by various autoantibodies not seen in RA. Additionally, the relative responses of the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) can be less well-correlated with each other in other diseases, particularly SLE, than in RA. Whereas both are commonly raised in RA, the CRP is often normal or only minimally elevated in patients with active SLE even when the ESR is elevated.",
"   </p>",
"   <p>",
"    Taken together, the pattern of long-standing disease, morning stiffness, symmetric arthritis, subcutaneous nodules, and the deformities characteristic of RA does not develop in these other disorders. There are several exceptions to this observation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Morning stiffness is common in all inflammatory arthritides. Symmetric arthritis is seen in patients with SLE and can be present in other disorders. Infrequently, nodules similar to those seen in RA may occur in patients with SLE, and other nodular lesions may mimic rheumatoid nodules. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link&amp;anchor=H10#H10\">",
"       \"Rheumatoid nodules\", section on 'Subcutaneous nodules'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link&amp;anchor=H9#H9\">",
"       \"Rheumatoid nodules\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An erosive arthritis has been described in some overlap syndromes, particularly those associated with anti-tRNA synthetases and anti-U1 RNP antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"       \"Clinical manifestations of mixed connective tissue disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Jaccoud's arthropathy occurs in up to 5 to 10 percent of patients with Sj&ouml;gren's syndrome or SLE and can also occur in sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=see_link\">",
"       \"Musculoskeletal manifestations of systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"       \"Sarcoid arthropathy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The joint deformities of Jaccoud's arthropathy are not caused by destruction of joints but by loosening and lengthening of periarticular structures and tendons. The ulnar drift or swan neck deformities caused by this disorder resemble RA superficially but can be distinguished by the fact that they are \"correctable\" on physical examination: fingers with these deformities can be moved manually back into normal alignment. In addition, radiographs in Jaccoud's arthropathy rarely reveal the cartilage loss, erosions, or cysts that are typical of longstanding RA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7379561\">",
"    <span class=\"h2\">",
"     Palindromic rheumatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palindromic rheumatism is characterized by episodes of joint inflammation sequentially affecting one to several joint areas for hours to days, with symptom-free periods that may last from days to months. Some patients presenting with this syndrome eventually develop a well-defined rheumatic disease, the most common being RA (ranging from 28 to 67 percent); some of the remaining patients develop SLE and other systemic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Patients with anti-CCP antibodies appear more likely to progress to definite RA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Close follow-up and specific serologic evaluation can help distinguish among these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features of rheumatoid arthritis\", section on 'Palindromic rheumatism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypermobility syndrome and fibromyalgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain, rather than stiffness or swelling, is the dominant symptom of the two common disorders, hypermobility syndrome and fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Although the hypermobility syndrome and fibromyalgia can both bear superficial resemblances to RA due to the presence of polyarthralgia, there are important distinguishing features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hypermobility syndrome is associated with hyperextensible joints, and patients lack signs of synovitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link\">",
"       \"Clinical manifestations and treatment of the hypermobility syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibromyalgia is associated with tender points at nonarticular sites such as at the medial portions of the elbows, across the trapezius muscle, and down the spine; there is no evidence of synovitis on examination, such as swelling, warmth, or diminished joint range of motion, although patients may exhibit joint line tenderness on exam. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neither the hypermobility syndrome nor fibromyalgia is associated with significant titers of rheumatoid factor or anti-cyclic citrullinated peptide antibodies or with elevated levels of acute phase reactants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although RA is normally not difficult to distinguish from fibromyalgia, a significant minority of patients with RA also develop fibromyalgia. The source of complaints in such patients needs to be carefully assessed to distinguish heightened pain sensitivity from pain related to inflammatory joint disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reactive arthritis and arthritis of IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive arthritis often presents as a monoarthritis or oligoarthritis in large joints, such as the knees, and RA may occasionally present in this fashion as well [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/26\">",
"     26",
"    </a>",
"    ]. The physical signs of both reactive arthritis and RA can be identical in the knees. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings on history, physical examination, or other assessments are more consistent with reactive arthritis than RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of recent urethritis or enteric infection",
"     </li>",
"     <li>",
"      Asymmetric pattern of joint involvement",
"     </li>",
"     <li>",
"      Symptoms or signs of enthesopathy (inflammation at the site where a tendon inserts into a bone, eg, the insertion point of the Achilles tendon into the heel)",
"     </li>",
"     <li>",
"      Keratoderma blenorrhagica or circinate balanitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link&amp;anchor=H9#H9\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\", section on 'Extraarticular signs and symptoms'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Radiologic evidence of sacroiliitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      spondylitis",
"     </li>",
"     <li>",
"      The presence of HLA-B27",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Involvement of the hands in reactive arthritis does not pose as great a diagnostic dilemma as that of the knees. Hand arthritis is more commonly asymmetric than in RA. Furthermore, reactive arthritis will often involve not only the joint but also the tenosynovium, entheses, and surrounding tissues of the digit, giving rise to a characteristic \"sausage\" swelling of the fingers (or toes if the feet are involved) (",
"    <a class=\"graphic graphic_picture graphicRef61696 \" href=\"UTD.htm?16/31/16881\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The arthritis associated with inflammatory bowel disease (IBD) or other gastrointestinal disorders is also part of the differential diagnosis. Patients with IBD may develop a peripheral polyarthritis with prominent involvement of the metacarpophalangeal joints that can be mistaken for RA; other presentations include predominantly large joint oligoarticular involvement or a spondyloarthropathy with sacroiliitis. This disorder may be missed if abdominal symptoms or symptoms of diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood or mucus in the stool are not prominent or are not specifically sought in the history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"     \"Arthritis associated with gastrointestinal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13373254\">",
"    <span class=\"h2\">",
"     Lyme arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme arthritis, a late manifestation of Lyme disease, occurs primarily in individuals who live in or travel to Lyme disease endemic areas. Lyme arthritis is characterized by intermittent or persistent inflammatory arthritis in a few large joints, especially the knee. The most commonly involved joints, after the knee, are the shoulder, ankle, elbow, temporomandibular joint, and wrist. Migratory arthralgias without frank arthritis may occur during early localized or early disseminated Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link\">",
"     \"Musculoskeletal manifestations of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of Lyme arthritis can usually be made by serologic testing, which should be performed in patients presenting with undiagnosed inflammatory arthritis in endemic areas. In addition, several clinical features help distinguish Lyme arthritis from RA. Unlike RA, for example, involvement of the small joints of the hands and feet is uncommon in patients with Lyme arthritis. Furthermore, many, but not all, patients with Lyme arthritis will describe an antecedent history of erythema migrans or other early disease manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=see_link&amp;anchor=H9#H9\">",
"     \"Musculoskeletal manifestations of Lyme disease\", section on 'Laboratory testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Psoriatic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriatic arthritis can be difficult to distinguish from RA because a symmetric polyarthritis can be observed in both disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/27\">",
"     27",
"    </a>",
"    ]. We generally make the diagnosis of psoriatic arthritis in such patients who also have psoriasis and are seronegative for RF and anti-CCP. However, we diagnose RA in those with a symmetric polyarthritis who are seropositive for at least one of these antibodies since skin psoriasis is so common. However, serologic testing and skin findings may not be informative, since patients with RA may not have RF or CCP antibodies (eg, seronegative RA) and the joint symptoms of psoriatic arthritis may precede the onset of skin disease by many years. Such patients should be evaluated and monitored for other signs more characteristic of psoriatic arthritis, such as nail changes or enthesitis; occasional patients exhibit overlapping features of both disorders.",
"   </p>",
"   <p>",
"    In some patients with a symmetric inflammatory polyarthritis, the only clue to the diagnosis of psoriatic arthritis is a family history of psoriasis. However, in the majority, the findings of skin psoriasis, nail changes (onychodystrophy), sausage toes or fingers, oligoarticular asymmetric large joint or spinal involvement,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthritis mutilans help distinguish the two entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164908\">",
"    <span class=\"h2\">",
"     Polymyalgia rheumatica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymyalgia rheumatica (PMR) can sometimes be mistaken for RA in patients presenting with more limited arthritis over the age of 50 who are seronegative or only have a low RF titer. Unlike RA, PMR is usually associated with marked myalgias in the shoulders and hips, and joint involvement tends to be milder, more limited, and more often asymmetric.",
"   </p>",
"   <p>",
"    Stiffness is thus more axial in PMR and more likely to be described as difficulty getting out of bed, while stiffness in the small joints of the hands and other involved joints predominates in RA, in which difficulty buttoning clothing is more likely to be reported. However, similar complaints to RA may be present in patients with PMR with synovitis affecting the small joints in the hands.",
"   </p>",
"   <p>",
"    The arthritis in PMR tends to respond strikingly to modest doses of glucocorticoids used to control other symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/28\">",
"     28",
"    </a>",
"    ]. In patients initially diagnosed with PMR, persistent or recurrent small joint arthritis with tapering of glucocorticoids and the absence of other findings suggestive of PMR may lead to a change in the diagnosis to RA after several months or even years of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Crystalline arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crystalline arthritis (gout and pseudogout) can become chronic and even assume a polyarticular distribution. The diagnosis is established by the finding of urate or calcium pyrophosphate crystals, respectively, in synovial fluids. The presence of tophi on physical examination, the detection of serological markers of RA, and the characteristic appearance of gouty erosions are also useful in distinguishing RA from polyarticular gout. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infectious arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious arthritis is usually monoarticular, but polyarthritis can occur. The diagnosis is established by culturing the pathogen from the synovial fluid or from the blood. Patients with septic arthritis may or may not appear toxic on examination, depending upon the stage of their infection, the presence of medications that can mask infection (eg, glucocorticoids), and other clinical variables. Peripheral blood leukocytosis with a left shift is common but not invariably present.",
"   </p>",
"   <p>",
"    A low threshold for suspecting infection is required, particularly in compromised hosts. Patients with RA are at increased risk for joint infections because a damaged joint can serve as a nidus of infection. Synovial fluid changes, including marked granulocytosis and low glucose levels, are similar to those seen in RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis (OA) can be confused with RA in the middle aged or older patient when the small joints of the hands are involved. However, different patterns of clinical involvement usually permit the correct diagnosis (",
"    <a class=\"graphic graphic_table graphicRef57005 \" href=\"UTD.htm?33/49/34587\">",
"     table 3",
"    </a>",
"    ). The following are examples (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      OA of the fingers typically affects the distal interphalangeal joints and is frequently associated with Heberden's nodes in this area. In contrast, RA typically affects the MCP and PIP joints and is not associated with Heberden's nodes.",
"     </li>",
"     <li>",
"      The carpometacarpal joint of the thumb is typically involved in OA.",
"     </li>",
"     <li>",
"      Swelling of the joints is hard and bony in OA. In contrast, soft, warm, boggy, and tender joints are typical of RA.",
"     </li>",
"     <li>",
"      Stiffness of the joint is a very common feature of RA but is relatively uncommon in OA. Furthermore, the stiffness of RA is characteristically worse after resting the joint (eg, morning stiffness), while the stiffness of OA, if present, is typically worse after any effort and is often described as evening stiffness. Morning stiffness in OA, when present, is usually transient or lasts no more than a few minutes, unlike the more sustained stiffness typical of RA.",
"     </li>",
"     <li>",
"      Radiographs also help distinguish RA from OA. OA is characterized by narrowing of the joint space due to cartilage loss and osteophytes due to bone remodeling, but not erosions or cysts.",
"     </li>",
"     <li>",
"      OA is classically associated with the absence of RFs and normal levels of acute phase reactants. However, RFs may be present, usually in low titer, consistent with the patient's (older) age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Paraneoplastic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint pain or frank polyarthritis can occur in association with cancer. The following are some examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myelodysplasia &mdash; Patients with myelodysplastic syndrome sometimes develop polyarthritis that mimics seronegative RA. In a cohort study of 87 patients with myelodysplastic syndrome, 5 had inflammatory arthritis that resembled RA [",
"      <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertrophic pulmonary osteoarthropathy &mdash; Patients with hypertrophic pulmonary osteoarthropathy typically demonstrate clubbing of the digits, joint pain, and periosteal new bone formation. Additionally, they give a characteristic history suggestive of bone pain and often describe the pain as deep and achy; nocturnal pain is common. Joint effusions may occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"       \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Multicentric reticulohistiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multicentric reticulohistiocytosis is a rare but highly destructive form of arthritis. The rapid joint destruction of multicentric reticulohistiocytosis resembles the arthritis mutilans occasionally observed in RA. Multiple smooth, shiny, erythematous nodules located in the periungual region suggest multicentric reticulohistiocytosis. Binucleated or multinucleated foreign body type giant cells are present on skin or synovial biopsies in multicentric reticulohistiocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a minority of patients, an underlying malignancy may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H3209395#H3209395\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Multicentric reticulohistiocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multicentric reticulohistiocytosis is relatively resistant to glucocorticoids and to disease-modifying antirheumatic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    . However, there are case reports of response to tumor necrosis factor-alpha inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] and to parenteral administration of an aminobisphosphonate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H129112367\">",
"    <span class=\"h2\">",
"     Sarcoid arthropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic arthritis in sarcoidosis may be oligoarticular or polyarticular and can appear similar to RA in some patients. It most frequently affects the ankles, knees, hands, wrist, and metacarpophalangeal and proximal interphalangeal joints, and it is frequently associated with parenchymal pulmonary disease.",
"   </p>",
"   <p>",
"    This disorder is distinguished from RA by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum concentrations of angiotensin converting enzyme (ACE) are found in up to 50 percent of patients.",
"     </li>",
"     <li>",
"      A chest radiograph may reveal characteristic findings of sarcoidosis.",
"     </li>",
"     <li>",
"      The pattern of acute arthritis with Lofgren&rsquo;s syndrome in patients with sarcoidosis is not observed in those with RA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"     \"Sarcoid arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Fibroblastic rheumatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroblastic rheumatism, a rare disease of unknown etiology, shares the features of arthralgia, arthritis, and nodules with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/55/6010/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Flexion contractures of the fingers occur in most patients, while thickened palmar fascia is noted in about one-half of reported cases. Biopsy of a nodule or thickened skin typically reveals increased thickness of collagen fibers and fibroblastic proliferation. Decreased elastic fibers and the presence of myofibroblasts are noted in approximately 50 percent. Radiographic findings are variable, but periarticular osteopenia and erosions may be noted.",
"   </p>",
"   <p>",
"    Due to the rarity of fibroblastic rheumatism, there is no well-established treatment. Progressive disease may lead to sclerodactyly and ankylosis of affected joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RA should be suspected in the adult patient who presents with inflammatory polyarthritis. The initial evaluation of such patients requires a careful history and physical examination, along with selected laboratory testing to identify features that are characteristic of RA or that suggest an alternative diagnosis. (See",
"      <a class=\"local\" href=\"#H8594869\">",
"       'Evaluation for suspected RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following components of the medical evaluation are helpful in making a clinical diagnosis of RA, both for the identification of characteristic findings and for the exclusion of other diagnoses (see",
"      <a class=\"local\" href=\"#H8594869\">",
"       'Evaluation for suspected RA'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A thorough medical history, with particular attention to joint pain, stiffness, and associated functional difficulties",
"     </li>",
"     <li>",
"      A complete physical examination to assess for synovitis, limited joint motion, extraarticular disease manifestations, and signs of diseases included in differential diagnosis",
"     </li>",
"     <li>",
"      Basic and selected laboratory testing, including assays for acute phase reactants (erythrocyte sedimentation rate and C-reactive protein), rheumatoid factor, anti-cyclic citrullinated peptide (CCP) antibodies, and antinuclear antibodies",
"     </li>",
"     <li>",
"      Selected imaging studies, including bilateral radiographs of the hands, wrists, and feet",
"     </li>",
"     <li>",
"      Arthrocentesis, if there is diagnostic uncertainty.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of RA can be made in a patient with inflammatory arthritis involving three or more joints, positive rheumatoid factor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anti-citrullinated",
"      <span class=\"nowrap\">",
"       peptide/protein",
"      </span>",
"      antibody, disease duration of more than six weeks, and elevated CRP or ESR, but without evidence of diseases with similar clinical features. (See",
"      <a class=\"local\" href=\"#H205867198\">",
"       'Our diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RA may also be diagnosed in patients without all of the classic findings of disease. This includes patients with seronegative RA, those with clinically quiescent disease, and those with recent onset RA. Such patients have",
"      <span class=\"nowrap\">",
"       findings/clinical",
"      </span>",
"      features that are generally consistent with those described as meeting the",
"      <span class=\"nowrap\">",
"       ACR/EULAR",
"      </span>",
"      classification criteria for RA. (See",
"      <a class=\"local\" href=\"#H10758726\">",
"       'Patients not meeting above criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 2010 classification criteria for RA were developed primarily for the identification for research purposes of patients with RA who are at high risk of persistent symptoms and joint injury unless treated with DMARDs. These criteria have replaced the 1987 criteria, which were based only upon patients with established disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Classification criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of RA includes multiple disorders that can generally be distinguished clinically or by limited laboratory testing, based upon a combination of the following features (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Limited duration (eg, in viral arthropathy)",
"     </li>",
"     <li>",
"      The presence of other diseases (eg, in psoriatic arthritis or arthritis of inflammatory bowel disease)",
"     </li>",
"     <li>",
"      The pattern of joint involvement and other symptoms (eg, in psoriatic arthritis, spondyloarthropathy, or polymyalgia rheumatica)",
"     </li>",
"     <li>",
"      The presence of systemic features (eg, in systemic lupus or dermatomyositis)",
"     </li>",
"     <li>",
"      Diagnostic laboratory tests associated with other conditions (eg, specific autoantibodies in SLE, synovial fluid crystals in gout or calcium pyrophosphate disease)",
"     </li>",
"     <li>",
"      Relatively high specificity of anti-CCP antibodies for RA",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/1\">",
"      Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010; 152:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/2\">",
"      Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/3\">",
"      Finckh A, Liang MH. Anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis: bayes clears the haze. Ann Intern Med 2007; 146:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/4\">",
"      Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/5\">",
"      Luime JJ, Colin EM, Hazes JM, Lubberts E. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 2010; 69:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/6\">",
"      Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/7\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/8\">",
"      Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/9\">",
"      Pincus T, Callahan LF. How many types of patients meet classification criteria for rheumatoid arthritis? J Rheumatol 1994; 21:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/10\">",
"      Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/11\">",
"      Smith CA, Petty RE, Tingle AJ. Rubella virus and arthritis. Rheum Dis Clin North Am 1987; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/12\">",
"      Smith CA, Woolf AD, Lenci M. Parvoviruses: infections and arthropathies. Rheum Dis Clin North Am 1987; 13:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/13\">",
"      Suhrbier A, La Linn M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004; 16:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/14\">",
"      Toivanen A. Alphaviruses: an emerging cause of arthritis? Curr Opin Rheumatol 2008; 20:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/15\">",
"      Simon F, Parola P, Grandadam M, et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine (Baltimore) 2007; 86:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/16\">",
"      Chopra A, Anuradha V, Lagoo-Joshi V, et al. Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum 2008; 58:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/17\">",
"      Sato K, Maruyama I, Maruyama Y, et al. Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum 1991; 34:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/18\">",
"      Venables PJ. Polymyositis-associated overlap syndromes. Br J Rheumatol 1996; 35:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/19\">",
"      Cronin ME. Musculoskeletal manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1988; 14:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/20\">",
"      Maksymowych WP, Suarez-Almazor ME, Buenviaje H, et al. HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. J Rheumatol 2002; 29:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/21\">",
"      Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol 2009; 36:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/22\">",
"      Salvador G, Gomez A, Vinas O, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology (Oxford) 2003; 42:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/23\">",
"      Russell AS, Devani A, Maksymowych WP. The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol 2006; 33:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/24\">",
"      Kirk JA, Ansell BM, Bywaters EG. The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility. Ann Rheum Dis 1967; 26:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/25\">",
"      Yunus M, Masi AT, Calabro JJ, et al. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981; 11:151.",
"     </a>",
"    </li>",
"    <li>",
"     Toivanen A. Reactive arthritis. In: Rheumatology, Klippel, Dieppe (Eds), Mosby, London 1994. p.491.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/27\">",
"      Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/28\">",
"      Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology (Oxford) 2009; 48:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/29\">",
"      Chandran G, Ahern MJ, Seshadri P, Coghlan D. Rheumatic manifestations of the myelodysplastic syndromes: a comparative study. Aust N Z J Med 1996; 26:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/30\">",
"      Barrow MV, Holubar K. Multicentric reticulohistiocytosis. A review of 33 patients. Medicine (Baltimore) 1969; 48:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/31\">",
"      Gorman JD, Danning C, Schumacher HR, et al. Multicentric reticulohistiocytosis: case report with immunohistochemical analysis and literature review. Arthritis Rheum 2000; 43:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/32\">",
"      Matejicka C, Morgan GJ, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum 2003; 48:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/33\">",
"      Calamia KT, Walsh JS, Bradley T, et al. Treatment of multicentric reticulohistiocytosis with etanercept: a case report (abstract). Arthritis Rheum 2003; 48:S618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/34\">",
"      Goto H, Inaba M, Kobayashi K, et al. Successful treatment of multicentric reticulohistiocytosis with alendronate: evidence for a direct effect of bisphosphonate on histiocytes. Arthritis Rheum 2003; 48:3538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/35\">",
"      Codriansky KA, R&uuml;nger TM, Bhawan J, et al. Multicentric reticulohistiocytosis: a systemic osteoclastic disease? Arthritis Rheum 2008; 59:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/36\">",
"      Fam AG, Hanna W, Mak V, Assaad D. Fibroblastic rheumatism: clinical and histologic evolution of cutaneous manifestations. J Rheumatol 1998; 25:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/37\">",
"      Lee JM, Sundel RP, Liang MG. Fibroblastic rheumatism: case report and review of the literature. Pediatr Dermatol 2002; 19:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/55/6010/abstract/38\">",
"      Pedersen JK, Poulsen T, H&oslash;rslev-Petersen K. Fibroblastic rheumatism: a Scandinavian case report. Ann Rheum Dis 2005; 64:156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7504 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-5AC2A9890B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6010=[""].join("\n");
var outline_f5_55_6010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8594869\">",
"      EVALUATION FOR SUSPECTED RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8594876\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H205867198\">",
"      Our diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H205867160\">",
"      - Inflammatory arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H205867167\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H205867174\">",
"      - Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10758726\">",
"      Patients not meeting above criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLASSIFICATION CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12499388\">",
"      2010 ACR/EULAR criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165301\">",
"      1987 ACR criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute viral polyarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Systemic rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7379561\">",
"      Palindromic rheumatism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypermobility syndrome and fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reactive arthritis and arthritis of IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13373254\">",
"      Lyme arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164908\">",
"      Polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Crystalline arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infectious arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Paraneoplastic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Multicentric reticulohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H129112367\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Fibroblastic rheumatism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7504\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7504|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/31/16881\" title=\"picture 1\">",
"      Sausage toe reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7504|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/13/4316\" title=\"table 1\">",
"      ARA criteria for RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/8/43149\" title=\"table 2\">",
"      Differential DX RA 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/49/34587\" title=\"table 3\">",
"      RA versus osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15576?source=related_link\">",
"      Chikungunya fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=related_link\">",
"      Clinical manifestations and treatment of the hypermobility syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36616?source=related_link\">",
"      Hematologic manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/7/9336?source=related_link\">",
"      Musculoskeletal manifestations of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=related_link\">",
"      Musculoskeletal manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42648?source=related_link\">",
"      Origin and utility of measurement of rheumatoid factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=related_link\">",
"      Sarcoid arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_55_6011="Ice therapy barrier effect";
var content_f5_55_6011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effects of barriers on magnitude of temperature reduction during ice therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physical barrier",
"       </td>",
"       <td class=\"subtitle1\">",
"        Skin temperature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Padded bandage",
"       </td>",
"       <td>",
"        30.5&deg;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bandage alone",
"       </td>",
"       <td>",
"        20.5&deg;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry washcloth",
"       </td>",
"       <td>",
"        17.8&deg;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No barrier",
"       </td>",
"       <td>",
"        10.8&deg;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Damp washcloth",
"       </td>",
"       <td>",
"        9.9&deg;C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: LaVelle BE, Snyder M. Differential conduction of cold through barriers. J Adv Nurs 1985; 10:55.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6011=[""].join("\n");
var outline_f5_55_6011=null;
var title_f5_55_6012="Common viral infections in SOT recipients";
var content_f5_55_6012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common viral infections in solid organ transplant recipients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Herpes group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein-Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HHV6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HHV7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HHV8/KSHV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Donor-derived",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        West Nile virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LCMV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Hepatitis B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Hepatitis C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Papillomavirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Polyomavirus BK/JC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Respiratory viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        RSV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parainfluenza",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metapneumovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SARS coronavirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Parvovirus B19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        HIV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6012=[""].join("\n");
var outline_f5_55_6012=null;
var title_f5_55_6013="Disease transformation in ET";
var content_f5_55_6013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hematologic transformation in six female patients with essential thrombocythemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease conversion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to conversion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment prior to conversion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cytogenetics at diagnosis of ET",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bone marrow at diagnosis of ET",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cytogenetics at time of conversion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Post conversion outcome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        AML",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        12 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Hydroxyurea x 12 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Not available",
"       </td>",
"       <td>",
"        Hypercellular",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        -5, add(17) (p11.2), der(3), der(6), der(14)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Death in 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        MMM",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        9 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Normal",
"       </td>",
"       <td>",
"        Normocellular",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Not available",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Doing well at 7 years post conversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        MMM",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        2 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Anagrelide x 1 year, Myleran x 2 weeks",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Normal",
"       </td>",
"       <td>",
"        Hypercellular",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Not available",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Died in a car accident 4 years after conversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        MMM",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        3 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Hydroxyurea x 6 months, Anagrelide x 3 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Normal",
"       </td>",
"       <td>",
"        Normocellular",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Not available",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Doing well at 8 years after conversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        PV",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        7 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Melphalan x 1 month",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Normal",
"       </td>",
"       <td>",
"        Normocellular",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Not available",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Doing well at 12 years after conversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        PV",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        6 years",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Hydroxyurea x 5 months",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Normal",
"       </td>",
"       <td>",
"        Normocellular",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Not available",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Doing well at 7 months post conversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No fibrosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AML: acute myeloid leukemia; MMM: myelofibrosis with myeloid metaplasia; PV: polycythemia vera.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Tefferi, A. American Society of Hematology Education Book 1999. Copyright &copy; 1999 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6013=[""].join("\n");
var outline_f5_55_6013=null;
var title_f5_55_6014="Management IRIS A";
var content_f5_55_6014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65960%7EID%2F78018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65960%7EID%2F78018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General management recommendations for specific IRIS-related syndromes*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common clinical manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General IRIS",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Consider concurrent unmasked infection, persistent active infection, antimicrobial resistance, adverse drug reaction, and medicine nonadherence.",
"       </td>",
"       <td>",
"        Generally self-limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M. tuberculosis",
"       </td>",
"       <td>",
"        <p>",
"         Pneumonia",
"        </p>",
"        <p>",
"         Lymphadenitis",
"        </p>",
"        <p>",
"         Intracranial tuberculomas",
"        </p>",
"        <p>",
"         Meningitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Consider the possibility of multidrug resistant TB.",
"        </p>",
"        <p>",
"         Incise and drain the initial episode of adenitis for diagnostic purposes and symptomatic relief.",
"        </p>",
"        <p>",
"         For moderate severity or CNS involvement, prednisone (1.0 mg/kg, up to 80mg daily) or dexamethasone 8-16 mg/day divided in twice daily doses and tapered after 1-2 months. Use as adjunct to anti-tuberculous therapy.",
"        </p>",
"        <p>",
"         Continue HAART&bull;.",
"        </p>",
"       </td>",
"       <td>",
"        Generally self-limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M. avium complex",
"       </td>",
"       <td>",
"        <p>",
"         Lymphadenitis",
"        </p>",
"        <p>",
"         Pneumonia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Incision and drainage or aspiration for the initial episode of adenitis.",
"        </p>",
"        <p>",
"         If illness is severe, adjunct corticosteroids (as above) in addition to standard anti-MAC therapy.",
"        </p>",
"        <p>",
"         Continue HAART.",
"        </p>",
"       </td>",
"       <td>",
"        Self-limited in the vast majority",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcus spp.",
"       </td>",
"       <td>",
"        <p>",
"         Meningoencephalitis",
"        </p>",
"        <p>",
"         Pneumonia",
"        </p>",
"        <p>",
"         Lymphadenitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Continue antifungal therapy.",
"        </p>",
"        <p>",
"         Adjunct corticosteroids, if illness is severe or not self-limited.",
"        </p>",
"        <p>",
"         Continue HAART&bull;.",
"        </p>",
"       </td>",
"       <td>",
"        Generally self-limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumocystis carinii",
"       </td>",
"       <td>",
"        Pneumonia",
"       </td>",
"       <td>",
"        <p>",
"         Standard course of anti-Pneumocystis antimicrobial therapy.",
"        </p>",
"        <p>",
"         Adjunct corticosteroids.",
"        </p>",
"        <p>",
"         Continue HAART&bull;.",
"        </p>",
"       </td>",
"       <td>",
"        Generally self-limited when corticosteroid therapy is used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Uveitis/vitritis",
"       </td>",
"       <td>",
"        <p>",
"         Continue HAART&Delta;.",
"        </p>",
"        <p>",
"         Anti-CMV antiviral therapy if concurrent CMV retinitis is present.",
"        </p>",
"        <p>",
"         Topical, intraocular, or systemic corticosteroids in conjunction with close ophthalmologic follow-up&loz;.",
"        </p>",
"        <p>",
"         Vitrectomy may be needed if vitreomacular traction occurs.",
"        </p>",
"       </td>",
"       <td>",
"        Generally good, but long-term sight-threatening complications may occur.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on published clinical experience, but needs to be proven in controlled clinical trials.",
"     <br>",
"      &bull; Consider delaying HAART therapy for 1-2 months if not already begun.",
"      <br>",
"       &Delta; Consider temporarily interrupting HAART for 1-3 months if eye, neural, liver, or other organ involvement is particularly severe, progressive, and/or steroid refractory.",
"       <br>",
"        &loz; Can alternatively use topical or systemic non-steroidal anti-inflammatory agents.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General management recommendations for IRIS-related syndromes, continued*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Most common clinical manifestations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prognosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        JC virus",
"       </td>",
"       <td>",
"        Progressive multifocal leukoencephalopathy with inflammatory features",
"       </td>",
"       <td>",
"        <p>",
"         Continue HAART in most cases.",
"        </p>",
"        <p>",
"         Corticosteroids.",
"        </p>",
"       </td>",
"       <td>",
"        Often self-limited, but chronic neurologic sequelae and fatal cases may occur.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HSV, VZV",
"       </td>",
"       <td>",
"        <p>",
"         Perianal herpes",
"        </p>",
"        <p>",
"         Localized zoster",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Continue HAART.",
"        </p>",
"        <p>",
"         Oral acyclovir or famciclovir for 7-14 days.",
"        </p>",
"       </td>",
"       <td>",
"        Self-limited in the vast majority",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td>",
"        Hepatitis",
"       </td>",
"       <td>",
"        <p>",
"         Consider direct drug hepatotoxicity (eg, protease inhibitor).",
"        </p>",
"        <p>",
"         Continue or interrupt HAART&Delta;.",
"        </p>",
"        <p>",
"         Tenofovir, lamivudine, emtricitabine, and/or entecavir if indicated.",
"        </p>",
"       </td>",
"       <td>",
"        Often self-limited, but progressive cirrhosis may occur, esp with low functional hepatic reserve.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C",
"       </td>",
"       <td>",
"        Hepatitis",
"       </td>",
"       <td>",
"        <p>",
"         Consider direct drug hepatotoxicity (eg, protease inhibitor).",
"        </p>",
"        <p>",
"         Continue or interrupt HAART&Delta;.",
"        </p>",
"        <p>",
"         Antiviral therapy may be an option in selected patients.",
"        </p>",
"       </td>",
"       <td>",
"        Same as above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus B19",
"       </td>",
"       <td>",
"        <p>",
"         Fever, anemia",
"        </p>",
"        <p>",
"         Encephalitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Intravenous immunoglobulin (IVIG).",
"        </p>",
"        <p>",
"         Continue or interrupt HAART&Delta;.",
"        </p>",
"       </td>",
"       <td>",
"        Usually self-limited.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        Pulmonary",
"       </td>",
"       <td>",
"        <p>",
"         Corticosteroids.",
"        </p>",
"        <p>",
"         Continue HAART.",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune thyroiditis",
"       </td>",
"       <td>",
"        Thryotoxicosis",
"       </td>",
"       <td>",
"        <p>",
"         Anti-thyroid drugs, beta-blockers, and/or thyroid ablation.",
"        </p>",
"        <p>",
"         Continue HAART.",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on published clinical experience, but needs to be proven in controlled clinical trials.",
"     <br>",
"      &Delta; Consider temporarilyinterrupting HAART for 1-3 months if eye, neural, liver, or other organinvolvement is particularly severe, progressive, and/or steroidrefractory.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6014=[""].join("\n");
var outline_f5_55_6014=null;
var title_f5_55_6015="FABERE test (Patrick test, "figure of four" test)";
var content_f5_55_6015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FABERE test (Patrick test, \"figure of four\" test)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The FABERE test (Patrick test or \"figure of four\" test) consists of",
"    <strong>",
"     F",
"    </strong>",
"    lexion of the hip and knee, with",
"    <strong>",
"     AB",
"    </strong>",
"    duction and",
"    <strong>",
"     E",
"    </strong>",
"    xternal",
"    <strong>",
"     R",
"    </strong>",
"    otation at the hip, so that the ankle of one leg is on top of the opposite knee (a figure four configuration). Force is applied downwards on the bent knee and the opposite hip, causing",
"    <strong>",
"     E",
"    </strong>",
"    xtension at the sacroiliac joint ipsilateral to the bent leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_55_6015=[""].join("\n");
var outline_f5_55_6015=null;
